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CHAPTER 1 INTRODUCTION
1.1.

Endothelial Progenitor Cell Discovery
The process of postnatal formation of blood vessels was traditionally

believed to result from proliferation of pre-existing mature endothelial cells, which
is termed angiogenesis[1]. Thanks to Asahara and coworkers’ isolation of
endothelial progenitor cells (EPCs) from human peripheral blood, our
understanding to the mechanism responsible for new blood vessel formation was
extended [2]. Their discovery of EPCs has introduced the concept of
vasculogenesis [2]. After that, postnatal vasculogenesis was defined as the
process that progenitor differentiate into mature endothelial cells and promote
postnatal new blood vessel formation [2, 3].
Since the discovery of EPCs by Asahara’s group, a substantial amount of
investigations showed that bone marrow-derived EPCs contribute to new blood
vessel formation by promoting the function of endothelium, incorporating into sites
of active neovascularization such as ischemic hind limbs, myocardium infarction,
and progressing tumors [4-7]. Recently, EPCs has been reported to be an
independent risk factor of cardiovascular diseases [8]. It is also reported that EPCs
are decreased in artery disease [9-11] but elevated in several types of cancer [12].
These studies have highlighted the potential importance of EPCs in
neovascularization or angiogenesis related diseases [13]. Understanding of EPC
biology provides us a better chance to manipulate EPCs and treat blood vessel
formation related diseases. EPCs can be easily obtained from bone marrow,
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peripheral blood, and spleen, and they can be expanded or manipulated in vitro
before transplantation.
1.2.

Classification of Endothelial Progenitor Cells.
In the bone marrow, EPCs are derived from mesodermal cells which

ultimately differentiate into endothelial cells [14, 15]. Since the discovery of EPCs
in 1997, different groups have tried to define and characterize this population.
However, despite those efforts and the increasing number of publications in EPC
biology, no exclusive definition of EPCs has been identified. So the EPC is
considered to be a group of cells that are derived from bone marrow, are able to
proliferate, and are able to differentiate from progenitor phenotype to mature
endothelial phenotype.
Different cell surface molecules have been mainly utilized to characterize
and define EPCs. Initially, three markers were used to characterize the early EPC:
CD133, CD34, and vascular endothelial growth factor receptor-2 (VEGFR2) which
is also known as Flk-1 or kinase insert domain (KDR) [16, 17]. EPCs from
peripheral blood express CD34 and VEGFR2 but no longer express CD133.
Endothelial cells are also negative for CD133 [18]. So loss of CD133 expression
is accompanied with EPC maturation.
During almost two decades of study, a variety of approaches to isolate
EPCs were developed, such as flow cytometry to analyze EPC markers [2, 19] and
several type of colony forming assays [8, 20-23]. These studies have indicated that
EPC is a type of heterogeneous cell population rather than a single type of cell
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population. Figure 1.1 showed the putative cascade of bone-marrow derived EPC
differentiation.

Figure 1.1 Putative origin and differentiation cascade of EPCs.
Schematic diagram shows the potential differentiation cascade of EPC from
hemangioblast cells. Figure is from [24]. Dash arrow line: Some isolated EPCs
possess endothelial-like cell surface marker but function as monocytes, indicating
the putative origin of that portion of EPCs is monocyte but lack of direct evidence.
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Although different nomenclatures have been used in attempting to
distinguish EPCs from other progenitor cells with angiogenic activities according
to their morphology, expression of cell surface markers, and cellular phenotype,
there is still no precise description to define them. One of the general
classifications of EPCs is based on the time they have been cultured in vitro,
according to which EPCs are divided into early and late EPC [25]. Generally, bone
marrow or peripheral derived mononuclear cells differentiated EPCs start to
emerge in fibronectin coated plated containing endothelial growth media within a
week, which is considered to be early EPCs. These cells have low proliferation
potential, display spindle shaped morphology and express VEGFR2 and VEcadherin, CD14 and CD45 [7, 26, 27]. These early EPCs can be cultured for 4
weeks, while continued culturing resulted in morphological and phenotypical
changes in the cells, such as loss of hematopoietic marker and gain of endothelial
marker [26]. Late EPCs started to emerge after 2-3 weeks in cell culture. Different
from early EPCs, late EPCs are more proliferative, and they incorporate into
endothelial monolayer more rapidly [25].
A variety of studies have reported the functional significance of early and
late EPCs. Early EPCs are reported to homing and incorporate into ischemic loci
to promote new blood vessel formation mainly by secreting angiogenic factors [7,
18, 28-31]. Late EPCs is reported to promote revascularization in a synergistic
manner with early EPCs [32]. Similar to early EPCs, in vivo studies have
demonstrated that administration of late EPCs into ischemic mice also resulted in
enhanced angiogenesis [7, 15, 33, 34]. Moreover, detailed studies indicated that
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late EPCs participate in the process of blood vessel formation by directly
incorporating into endothelial network and provide building blocks for
neovascularization [4, 35, 36].
1.3.

EPC mobilization and homing
EPCs reside in the stem cell niche of bone marrow which also contains

fibroblasts

and

osteoblasts.

Certain

cytokines

secreted

from

local

microenvironments interrupt the interaction between EPCs and bone marrow
stromal cells and improve the EPC transendothelial migration to promote the EPC
entering the circulation system. A variety of chemokines and growth factors have
been reported to contribute to EPC mobilization. Stromal derived factor 1 (SDF-1)
has been documented to play critical roles in EPC mobilization, especially in the
situation of ischemia. It is reported that disruption of SDF-1 mediated interaction
between EPC and bone marrow stromal cells and elevation of circulating SDF-1
are important for EPC mobilization. Moreover, it is believed that SDF-1 mobilize
EPCs in a matrix metalloproteinase 9 (MMP-9) dependent manner [37]. The SDF1/CXCR4 signaling pathway has been reported to play important roles in EPC
biology [38, 39].
Vascular endothelial growth factor (VEGF) has also been reported to
contribute to EPC mobilization through promoting EPC proliferation and increasing
the expression of MMP-9 [40]. Erythropoietin (EPO), colony stimulating factor (GCSF) and granulocyte monocyte colony stimulating factor (GM-CSF) are also
reported to be able to increase circulating EPC amount by stimulating EPC
proliferation [41-44]. Moreover, in vitro and in vivo studies have demonstrated that
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CXCL5 and CXCL8, which have been considered as pro-inflammatory
chemokines at the beginning, also play important roles in EPC mobilization [45].
Mediated mainly by chemokine/chemokine receptor axis, EPCs will home
to the sites of ischemia or vascular injury to participate in blood vessel formation
either directly or indirectly. Accumulating evidence have shown that several
chemokine/chemokine receptor pairs play major roles in regulating EPC homing.
Monocyte chemoattractant protein-1 (MCP-1), which is one of the CCR2 ligands,
is present in the sites of endothelial denudation [46]. It is also reported that MCP1/CCR2 axis is essential for directing EPCs into tumor neovessels [47]. Moreover,
it is well documented that SDF-1/CXCR4 axis acts as a key element for EPC
recruitment towards hypoxic gradient and arterial injury sites [48, 49].
Recently, the in vivo studies have revealed the importance of CXCR2, a
CXC chemokine receptor which was initially identified in leukocyte recruitment [50],
in EPC recruitment [51]. In the study, CXCL1 and CXCL7, which are both CXCR2
ligands, were able to arrest flowing EPCs, and blockade of CXCR2 attenuated the
recruitment of EPCs [51, 52]. Furthermore, it has also been reported that CXCL12
and CXCL7 mediated the homing of EPC at early stage after arterial injury and
later stage of which was mediated by CXCL1 [53].
1.4.

Paracrine action of EPC
During the process of investigating EPC biology, some groups have noticed

that the observed beneficial effects were not proportional to the amount of
incorporated EPCs, indicating certain unidentified roles that EPCs have played
during those processes. Growing evidence indicates that EPCs participate in
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maintaining the integrity of vascular structure by improving blood vessel formation
through both secreting proangiogenic factors and incorporating into endothelial
network to differentiate into mature endothelial cells. Reports from multiple groups
have supported this notion that EPC is an important source of chemokines and
growth factors. It is believed that EPCs release factors that promote the functions
of resident mature endothelial cells [18, 54]. Recently, it is reported that under
hypoxic condition EPCs secret several kinds of chemokines and growth factors
including CXCL1, SDF-1, VEGF, and macrophage migration inhibitory factor (MIF),
which promoted the EPC adhesion, migration, and transmigration through
endothelial layers [55]. In agreement with this finding, another group has also
detected several chemokines, such as growth-regulated protein-α (GROα), CXCL8, EGF, and MCP-1, in EPC conditioned medium. Furthermore, the authors also
found that the EPC-conditioned medium promoted endothelial cell viability, cell
migration, and angiogenesis through phosphoinositide 3-kinase/protein kinase B
(PI3K/Akt) and mitogen-activated protein kinase-kinase/ extracellular signalregulating kinase (MEK/ERK) pathways [56]. Moreover, the paracrine factors
secreted by EPCs were also able to protect endothelial cells from apoptosis and
promote their angiogenic potency [57]. These secreted factors not only exert their
activities on endothelial cells but also promote the EPCs’ function, such as
incorporating into growing capillaries [25].
Based on the previous findings, it is clear that EPCs need to undergo
multiple steps in order to contribute to the regeneration of blood vessel as shown
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in Figure 1.2. Dysregulation of any step during this process will prevent EPCs
performing normal functions, which can be observed in diseases.

Figure 1.2 EPCs contribute to blood vessel regeneration.
EPCs need to undergo multiple steps including mobilization, chemotaxis, invasion,
migration, differentiation, as well as pro-angiogenic factor secretion to contribute
to the blood vessel formation. (Figure adopted from [15])

9

1.5.

EPCs and diseases
The first report describing the contribution of EPC to tumor related

vasculogenesis was in 2001 [58]. Lyden et al. demonstrated that bone marrow
from wild-type mice, rather than that from angiogenesis-defective Id-mutant mice,
restored tumor angiogenesis and growth [58]. The contribution of EPCs to tumor
blood vessel formation varies among different studies. Meanwhile, clinical study
has also been carried out in patients suffered from cancer after bone marrow
transplantation. The contribution of bone marrow derived EPCs to tumor
angiogenesis varies from 1% to 12.1% [59]. On the other hand, EPCs also
contribute to the tumor vascularization indirectly through their paracrine activity. It
has been reported that blocking EPC mobilization has significantly reduced the
tumor angiogenesis and progression [60]. Other groups also demonstrate that
EPCs promote angiogenesis by releasing pro-angiogenic factors, such as VEGF
and SDF-1 [61, 62]. Because of their contribution to tumor related vascularization,
EPCs have been considered to be a potential biomarker in various clinical studies
as shown in Table 1.1 (Reviewed in [63]). In summary, accumulating evidence
indicates that EPCs contribute to tumor related blood vessel formation directly and
indirectly, and consequently, they have been considered as a potential tumor
biomarker.
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Table 1.1 Studies evaluating circulating EPCs levels compared to healthy controls
in cancer patients. Modified from [63]
Author/Year

Cancer types

EPC definition

Circulating
EPC levels

P value

Ho/2006

Hepatocellular
Carcinoma

CD34+ CD133+

Increased

<0.01

Dome/2006

Non-Small Cell Lung
Cancer

CD34+ VEGFR2+

Increased

<0.002

Zheng/2007

Glioma

CD34+ CD133+
VEGFR2+

increased

<0.001

Yu/2007

Hepatocellular
Carcinoma

CD34+ CD133+

Increased

<0.01

RichterEhrenstein/2007

Breast Cancer

CD34+ VEGFR2+

Increased

<0.001

Brunner/2008

Head and Neck Cancer

CD133+ VEGFR2+

Increased

<0.001

Bogos/2009

Small Cell Lung Cancer

CD34+ VEGFR3+

Increased

<0.01

Sieghart/2009

Hepatocellular
Carcinoma

CD34+ CD133+
VEGFR2+

Increased

<0.01

Goon/2009

Breast Cancer

CD34+ VEGFR2+

Increased

<0.05

Rafat/2010

Glioma

CD34+ VEGFR2+

Increased

<0.05

Nowak/2010

Lung Cancer

CD34+ CD133+
VEGFR2+

Increased

<0.001

Su/2010

Ovarian Cancer

CD34+ VEGFR2+

Increased

<0.01

VEGFR2+
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Table 1.1 Continued
Author/Year

Cancer types

EPC definition

Circulating
EPC levels

P value

Bhatt/2011

Renal Cell
Carcinoma

CD34+ CD133+
CD146+ CD45-

Increased

<0.01

Bhaskar/2012

Multiple
Myeloma

CD31+ CD34+
CD133+ CD45-

Increased

<0.001

Yang/2012

Renal Cell
Carcinoma

CD34+ VEGFR2+
CD45-

Increased

<0.001

Qiu/2013

Ovarian
Cancer

CD34+ VEGFR3+

Increased

<0.01

Ha/2013

Gastric Cancer

CD34+ CD133+

Increased

<0.05

Ramcharan/2013

Colorectal
Cancer

CD34+ VEGFR2+
CD45-

Increased

<0.001

Kim/2014

Ovarian
Cancer

CD31+ CD133+
VEGFR2+ CD45-

Increased

<0.05

Kim/2014

Cervical
Cancer

CD31+ CD133+
VEGFR2+ CD45-

Increased

<0.01
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Moreover, increasing body of evidence has demonstrated the correlation
between the amount and function of EPCs and the cardiovascular disease risk
factors

which

includes

diabetes,

hypertension,

aging,

smoking,

and

hypercholesterolemia.
Diabetes is a critical cardiovascular risk factor and it is negatively
associated with circulating EPC number and function. EPC dysfunction is a major
problem in diabetes related cardiovascular symptoms and vascular complications
[10, 64-66]. Under the diabetic conditions, the number of circulating EPCs are
decreased. In both type 1 and type 2 diabetic patients, the amount of circulating
EPCs are decreased compared to the healthy control subjects [10, 66-68]. Along
with the decrease in the EPC counts, findings from clinical studies indicate that the
EPC functions, such as proliferation, adhesion, and incorporation, are also
impaired under the conditions of diabetes [10, 64, 69-71]. These impairment in
EPC functions may be due to their decreased response to stimuli [72, 73] and
dysfunction in paracrine abilities [10].
The EPC counts and functions are also negatively related to aging, which
is an important cardiovascular disease risk factor. It has been reported that EPCs
from younger mice restored the impaired blood vessel formation in older mice [74].
In clinical studies, decreased circulating EPC number with aging in patients with
coronary artery disease have also been described by several groups [9, 75]. It has
been proposed that the aging related EPC dysfunction may result from reduced
levels of pro-angiogenic factors, enhanced senescence, and accelerated
apoptosis [8, 76-78].
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Lipid metabolism such as hypercholesterolemia has also been related to
circulating EPC number and function. It has been reported that EPCs from patients
with hypercholesterolemia display impaired proliferation, migration and adhesion
activities [79, 80]. Meanwhile, increasing evidence has demonstrated the
association between EPC number and function with other cardiovascular disease
risk factors such as smoking and hypertension [9].
It is considered that mobilized EPCs migrate to the injured vascular, such
as ischemic tissue or infarcted cardiomyocyte, to promote vascularization and
tissue repair [7, 81-83].

Many pre-clinical investigations have confirmed the

therapeutic potential of EPCs by using animal models with myocardial infarction
and hind limb ischemia [54, 84]. In the clinical studies, EPCs also displayed their
therapeutic capacities. A large number of pre-clinical studies have shown that
patients with cardiovascular disease and severe leg ischemia benefited from EPC
administration as shown in table 1.2. (Reviewed in [69])
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Table 1.2 Therapeutic effect of EPC therapy
Author

Disease

n

Method of delivery

Effects

Perin

Severe

21

Intramyocardial injection

Myocardial

perfusion↑;

EF↑;

ESV↓

ischemic
heart failure
Strauer

Acute MI

10

Intracoronary infusion

Infarct area↓, ESV↓;
Myocardial viability↑; SV↑

Assmus

Acute MI

40

Intracoronary infusion

EF↑; Local contractility↑
Myocardial viability↑
Coronary flow reserve↑; ESV↓

Wollert

Acute MI

30

Intracoronary infusion

EF↑

Fernandez-

Acute MI

20

Intracoronary infusion

EF↑; Local contractility↑; ESV↓

Hamano

CABG

5

Injection in myocardial CABG

Myocardial perfusion↑

Tateishi-

Severe

25

Injection into the gastrocnemius

ABI↑; physical tolerance↑;

Yuyama

ischemia

muscle

tissue perfusion↑; Rrest pain↓

Aviles

leg

Therapeutic of injection based EPC therapy in different diseases. CABG, coronary
artery bypass graft; MI, myocardial infarction; EF, ejection fraction; ESV, end
systolic volume; SV, stroke volume; LV, left ventricle; ABI, ankle-brachial index.
(Table is adopted from Shantsila et al [69])
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1.6.

GPCR overview
G protein-coupled receptor, which is also known as seven transmembrane

receptor, is a superfamily of integral membrane proteins containing one
extracellular N-terminus, three intracellular loops, three extracellular loops, and
one intracellular C-terminus [85]. GPCRs contain one of the largest and most
investigated population of proteins in mammalian genomes [86]. GPCRs can be
detected in all types of tissues and they participate in a variety of cellular activities.
GPCRs transduce extracellular signals into the cells and regulate cellular activities
through their bound G proteins [85, 87, 88]. G proteins, also known as guanine
nucleotide-binding proteins, are composed of three non-identical subunits which
are α, β, and γ subunits [89]. Each subunit contains several isoforms, which makes
a variety of combinations of G proteins, resulting in the complex network of
signaling transduction [89, 90]. G protein is reported to be associated with the third
intracellular loop of the GPCRs, and binding of ligands to GPCRs results in their
conformational change and, consequently, release of the heterotrimeric G proteins
which further activate downstream signaling molecules, such as phospholipase C
beta (PLC-β) and adenylyl cyclase (AC) [89, 91-93] (as shown in Table 1.3).
Unregulated GPCRs have been reported in a variety of pathological conditions
including cancer development and progression [94-96]. Accordingly, GPCR are
also considered as a potential therapeutic target by pharmaceutical companies,
and nearly 40% of modern drugs target GPCRs [97]. Moreover, those drugs have
only targeted a small portion of identified GPCRs. On the other hand, there are still
large amount of GPCRs, whose functions and ligands are still not clear, have been
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termed as orphan receptors [98-100]. Further studying GPCRs will improve our
understanding of this group of proteins and eventually improve the development
of disease therapies.

Table 1.3. G-protein subunits and their functions. (modified from [89])
G-protein

Effector

Effect

α-subunit
Gαi1 Gαi2 Gαi3 GαoAB Gαz

Adenylyl cyclase

Inhibition

Gαt1 Gαt2 Gαgust

Phosphodiesterase

Activation

Gαs GαsXL Gαolf

Adenylyl cyclase

Stimulate

Gαq Gα11 Gα14-16

Phospholipase Cβ

Stimulate

Gα12 Gα13

Rho guanine nucleotide-exchange factors

Stimulate

Phospholipase A, Phospholipase Cβ1-3,
Adenylyl cyclase (type II, IV),

Activation

N-type calcium channel, P/Q-type calcium
channel, Adenylyl cyclase (type I, III, V, VI,
VII), PI3K, p21-activated protein kinase

Inhibition

Gβγ-subunit

1.7.

GPCR signaling
G proteins are composed of three non-identical subunits [89]. G proteins

usually exist in the heterotrimeric form containing α, β, and γ subunit [101, 102]. It
is reported that α subunit contains 17 isoforms, the β subunit contains 5 isoforms,
and γ subunit has 12 isoforms [89, 90]. When bound to GDP, the α subunit forms
the complex with βγ heterodimer and associate with GPCRs, and when the α
subunit binds GTP, it functionally dissociates from the βγ complex and regulates
the downstream signaling effectors [91]. Generally, G proteins are termed
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according to α subunit, which give rise to the Gs (contains Gαs); Gq (includes Gαq);
Gi (includes Gαi); and so on. Gs couples to a large number of GPCRs and activates
AC, which is responsible for the synthesis of the second messenger, cyclic AMP
(cAMP). On the other hand, Gi inhibits the cAMP synthesis by inhibiting the activity
of adenylyl cyclase. Gq is reported to stimulate PLC-β, and Gα12 activates the
activities of Rho-Guanine Nucleotide Exchange Factors (GEFs) [89, 103].
Meanwhile, β and γ subunits function in the form of heterodimer are also capable
of transducing signaling toward its own downstream effectors, such as PLC-β, AC,
and K+ channels [104-108] (as shown in table 1.3). Moreover, G proteins have also
been reported to activate p38 mitogen-activated protein kinase (p38MAPK),
extracellular signaling-related protein kinase (ERK1/2), and c-Jun N-terminal
kinase (JNK) pathways [109-112].
1.8.

Chemokine and CXCR2
Chemokines are a subtype of chemotactic cytokines, which were identified

as cytokines that activated neutrophils [113]. They exert their activities to regulate
cellular functions through GPCRs [114-116]. Based on the spacing of the first two
cysteines at the N-terminus, chemokines have been divided into four subgroups:
C, CC, CXC, and CX3C chemokines, in which X represents any non-cysteine
amino acids [117-119] as shown in Figure 1.3. Within the chemokine sub-families,
CXC chemokines are further classified into two categories based on the presence
of a specific short peptide sequence: glutamic acid-leucine-arginine (ELR) at the
N-terminus. Accordingly, CXC chemokine are subclassified into ELR+ and ELRCXC chemokines [120]. ELR+ CXC chemokines include: interleukin-8 (IL-
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8/CXCL8),

epithelial

neutrophil

activating

protein-78

(ENA-78/CXCL5),

granulocyte chemotactic peptide-2 (GCP-2/CXCL6), neutrophilic activating protein
(NAP-2/CXCL7), melanoma growth stimulatory activities (GROα,β,γ/CXCL1-3)
[117]. It has been well accepted that ELR+ CXC chemokines are actively involved
in angiogenesis [121, 122], recruitment of stromal cells to tumor microenvironment,
and cancer progression [96]. By contrast, ELR- CXC chemokines, platelet factor4 (PF-4) has been shown to have angiostatic properties [120]. Since Murphy et al
identified the CXCR1 and CXCR2 in neutrophils in 1991, more and more
chemokine receptors have been identified [123]. These chemokine receptors
share several common properties. All of them are integral membrane proteins
containing one extracellular N-terminus, three intracellular loops, three
extracellular loops, and one intracellular C-terminus [85]. These chemokine
receptors can be modified through glycosylation at their N-terminus, and their
activities can be regulated by serine and threonine phosphorylation at their
intracellular C-terminus. Moreover, the cysteines located at the first and second
extracellular loops usually form a disulfide [124]. Generally, many chemokines
have more than one receptors and many chemokine receptors have multiple
ligands [117]. For example, ELR+ chemokine IL-8 stimulates both CXCR1 and
CXCR2, which are highly homologous [123, 125]. CXCR1 binds to IL-8 or CXCL6,
however, CXCR2 is able to interact with CXCL1, 2, 3, 5, 6, 7 and 8 [116].
CXCR2 is widely expressed in a variety of cell types including neutrophils
[50], epithelial cells [96], smooth muscle cells, monocytes, and endothelial
progenitor cells [45]. It has been reported to be involved in multiple cellular
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activities such as cell proliferation, migration, angiogenesis, as well as survival [50,
96]. Activated by its ligands, G protein dissociates from CXCR2 and activate
different downstream effectors such as cAMP/PKA, PKC, PLC, PI3K/AKT,
Ras/Raf/MAPK, and even NF-κB pathways to regulate different cell functions [126129].

Figure 1.3. Classification of chemokine.
Based on the spacing of the first two cysteines at the N-terminus, chemokines have
been divided into four subgroups: C, CC, CXC, and CX3C chemokines, in which
X represents any non-cysteine amino acids. CX3C chemokines possess additional
mucin-like domain and cytoplasmic domain. (Figure from [130])
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1.9.

PDZ domain, PDZ motif and PDZ mediated protein-protein interaction
PDZ domain, the name of which comes from the first three proteins

observed containing this domain: post synaptic density protein 95 (PSD-95),
Drosophila disc large tumor suppressor (Dlg1), and zonula occludens-1 protein
(ZO-1), mediates protein-protein interactions by recognizing and physically
interacting with short binding motifs which usually is located at the carboxyl termini
of proteins [131, 132]. Previous studies from our lab and others’ have
demonstrated that PDZ domain mediated protein-protein complexes play
important roles in facilitating signaling transduction in different types of cells [50,
96, 133]. Composed of one β strand and one α helices, the binding groove of PDZ
domain specifically recognize and bind the short binding motif, which is usually 4
~ 5 residues in length, referred as PDZ motif [134, 135]. The nomenclature for the
PDZ motif is defined as follows: the last amino acid at carboxyl terminal amino acid
is defined as P0 residue, and subsequently, the rest of the residues towards the
amino terminus are named as P-1, P-2, P-3, etc. [136]. Oriented peptide library
approach was used to study the preference of amino acids within this PDZ motif
[136]. Comprehensive previous studies indicated that the P 0 and P-2 residues are
the most critical residues for recognition and physical interaction between PDZ
motif and PDZ domain [136]. Specific hydrophobic amino acids, Valine (V) and
Leucine (L), are preferred at P0 position for PDZ domain recognition and binding
[134, 137]. Meanwhile, the amino acid preference at P-2 position varies, the amino
acid there could be hydroxylated, charged or hydrophobic [138]. Based on the
bound PDZ motif, PDZ domains are classified into several subgroups [138, 139].

21

Generally, they are divided into three classes: class I PDZ domains specifically
recognize S/T-X-φ-COOH [89, 90] (φ represents hydrophobic amino acid residue
and X represents any amino acid residue); class II PDZ domains specifically
recognize the φ-X-φ-COOH [85, 91]; and class III PDZ domains recognize the motif
X-X-C-COOH [140, 141]. Moreover, there are a few other PDZ domains that do
not fit into this classification [142-144]. Proteins containing PDZ domains, such as
Na+/H+ exchange regulatory factor 1 (NHERF1) and Na+/H+ exchange regulatory
factor 2 (NHERF2), provide scaffold for organization of both membrane receptors
or ion channels and downstream effectors to proximity location, leading to
facilitated signaling transduction. Based on the status of possessed PDZ domains,
PDZ domain containing proteins (PDZ proteins) can be divided into two groups:
ones that only contain PDZ domain, NHERF1 and NHERF1; and proteins that
contain PDZ domain along with other domains, such as membrane-associated
guanylate kinase (MAGUK) proteins [82]. Within the groups of proteins that contain
PDZ domain(s) only, NHERF1 which is also called ezrin/radixin/moesin-binding
phosphoprotein 50 (EBP50), as well as its isoform NHERF2 are expressed in a
variety types of cells. Possessing two highly homologous PDZ domains, PDZ1 and
PDZ2, NHERF1 and NHERF2 provide scaffold for a variety of signaling proteins
including GPCRs [133]. Also, both NHERF1 and NHERF2 regulate a wide range
of cell signaling and cellular events [145]. They usually function as scaffold proteins
to associate with membrane receptors and their downstream effectors. CXCR2
possesses a PDZ motif (-S-T-T-L) at tis carboxyl termini, meanwhile, its
downstream effector, PLC-β isoforms, also contain consensus PDZ motif (-X-S/T-
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X-L/V). Our previous studies have demonstrated that class I PDZ domain mediated
multiprotein complex, including CXCR2, NHERF1, PLC-β, play important roles in
facilitating specific and efficient signaling transduction in different cell lines [50, 96]
(Figure 1.4).

Figure 1.4. Structure of NHERF1 PDZ2 in complex with CXCR2 C-terminus
containing PDZ motif and NHERF1 PDZ1 in complex with PLC-β3 C-terminus with
PDZ motif.
(A). Ribbon diagram of NHERF1 PDZ2 recognizes CXCR2 PDZ motif. PDZ2 is
shown in orange and CXCR2 C-terminus peptide is shown in blue. (B). Ribbon
diagram of NHERF1 PDZ1 recognizes PLC-β3 C-terminus peptide. PDZ1 is shown
in green and PLC-β3 is shown in magenta. For both PDZ1 and PDZ2, the α-helices
and β-strands are labeled according to their position in the sequence. (Diagrams
are modified from [146, 147])
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1.10. CXCR2 in angiogenesis
Angiogenesis plays important roles in multiple biological processes, such
as wound healing and tumor progression [148, 149]. Ligands of CXCR2 such as
CXCL1, CXCL2, CXCL3, CXCL5, and CXCL8 have been reported to be critical in
promoting angiogenesis, and these findings have highlighted the significance of
CXCR2 in angiogenesis [150-154]. Moreover, through corneal micropocket assays,
the angiogenic activity induced by CXCR2 ligands was significantly attenuated in
the presence of CXCR2 neutralizing antibody or under the condition of CXCR2
depletion [155]. Meanwhile, CXCR2 has also been reported to promote endothelial
cell tube formation, proliferation, and inhibit endothelial cell from apoptosis [156].
Cellular functions of endothelial cells such as migration and proliferation
also play important roles during the process of angiogenesis. CXCL1 was reported
to be able to enhance human umbilical vein endothelial cell proliferation [157]. It
has also been demonstrated that CXCL1 promotes endothelial cell migration and
proliferation through ERK1/2 and p38 MAPK signaling pathways [157, 158].
1.11. CXCR2 in EPC
EPCs are defined according to expressing markers of progenitor,
possessing the capacity of colony-forming, and being able to differentiate into
endothelial cells. According to these characteristics, EPCs play important roles in
blood vessel formation directly and indirectly, which contain multiple steps. The
CXCR2 has also been detected in EPCs in previous studies and it has been shown
that CXCR2 regulates several EPC activities such as homing, transmigration, and
reendothelialization [51, 159, 160]. Findings from previous studies showed that

24

multiple CXCR2 ligands are positively involved in EPCs activities. It has been
demonstrated that CXCL1 and CXCL7, function through their receptor CXCR2,
play critical role in EPC recruitment, adhesion, and incorporation during the
multiple steps after arterial damage [53]. More specifically, during the process of
homing to the arterial injury sites, CXCL1 and CXCL7, promote the adhesion of
EPCs to fibronectin or integrin ligands. Accordingly, CXCR2 is termed as an arrest
receptor in EPCs. Compared to CXCR4, which plays critical roles in EPC
mobilization, CXCR2 is more important during EPC recruitment [51, 159]. Another
CXCR2 ligands, CXCL8, is also involved in CXCR2 mediated EPC transwell
migration and capillary tube formation. Previous studies have shown that under
hypoxic condition, upregulated expression of CXCL8 from ischemic tissue
mediates EPC migration toward chemotaxis gradient [161, 162]. Furthermore,
CXCL8 axis also regulates the angiogenic, proliferative, and migratory activities in
mature endothelial cells in both paracrine and autocrine manner [156, 163]. Under
certain pathological conditions environmental circumstances also influence the
behaviors of EPCs, sometimes through affecting chemokines and chemokine
receptors. In blood vessel formation related disorders, ischemia is one of the major
environments. Hypoxic condition has been reported to upregulate the expression
of CXCR2 and its cognate ligand, CXCL1, in EPCs. In the presence of
CXCL1/CXCR2, the transmigration, adhesion, and angiogenic potencies of EPCs
have been stimulated. Moreover, CXCL1/CXCR2 axis is believed to play crucial
roles in initiating of neovascularization by recruiting EPCs [55]. Similarly, IL-8
secreted by ischemic cardiac endothelium is also reported to function as a
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mediator for EPC myocardial homing by generating a chemoattractant gradient
[162].
1.12. Rho GTPase and RhoA/ROCK signaling
Small GTPases are composed of a large population of hydrolase enzymes
that function independently as molecular switches to regulate a variety of cellular
activities. Activated by guanine nucleotide exchange factors (GEF) and inactivated
by GTPase-activating proteins (GAP), small GTPases cycle between GTP bound
active conformation and GDP bound inactive conformation. When they are
activated, GTP bound GTPase will transduce signaling toward their downstream
effectors until the GTP is hydrolyzed as shown in Figure 1.5. Among hundreds of
GTPases, Rho, Rac, and Cdc42 belong to Rho GTPase subfamily, are the three
most extensively studied members. Their contributions to the regulation of
cytoskeleton assembly and regulation have been well demonstrated in a variety of
cell lines. It has been shown that, Cdc42 and Rac are involved in mediating
membrane protrusion while RhoA regulates the membrane retraction in fibroblasts.
RhoA has been reported to mediate the wound closure [164, 165]. Moreover, these
members of Rho GTPases are also associated with regulating cellular activities
other than cell motility. They were reported to regulate cell polarity, G1 cell cycle
progression, proliferation, and survival [166].
Among these well studied GTPase, RhoA and its principle effector Rhoassociated kinase (ROCK)， which is a serine/threonine protein kinase, have been
the study subjects of a variety of groups [167]. Involved in cytoskeleton
organization, the RhoA/ROCK signaling axis has been shown to contribute to the
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regulation of several cellular events, such as cell focal adhesion and stress fiber
assembly [168], activation of integrin [169], migration, contraction, proliferation,
cell cycle progression, survival, and apoptosis [170]. A growing body of evidence
from basic research and clinical study suggest that RhoA/ROCK signaling axis play
important roles the development of cardiac structure and conduction system during
embryonic [171, 172]. Accordingly, RhoA/ROCK signaling pathway have been
demonstrated to be associated with several cardiovascular diseases, including
hypertension, coronary artery spasm, ischemic stroke, pulmonary hypertension,
and heart failure [173-177]. Moreover, recruitment of bone marrow derived cells
has also been attenuated under the condition of ROCK deficiency [178].
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Figure 1.5. Regulation of Rho GTPase activity.
Rho GTPase cycles between GDP-bound (inactive) and GTP-bound (active)
states. GEFs stimulates the release of GDP from Rho GTPase, which allows it to
binding GTP. GAP hydrolysis the GTPase bound GTP to inactivate it. GDI binds
to GDP-bound Rho GTPase to prevent it from activation and keep it away from the
plasma membrane, which is their place for action.
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As RhoA exerts its activities mainly through ROCK proteins to regulate a
variety of cellular activities, ROCK proteins have also been studied. The ROCK
family has two members, ROCK1 and ROCK2, which share 92% homology in their
catalytic domains. Selective inhibitors, such as Y27632 [179] and fasudil [180],
targeting ROCKs at their ATP-dependent kinase domain have been used to study
the role of RhoA/ROCK signaling axis in different disorders. RhoA/ROCK and their
downstream targets are responsible for cell migration and motility, and Y27632 or
siRNA targeting ROCKs attenuated the RhoA/ROCK mediated cell migration and
proliferation in different cell lines [181-187]. Moreover, the roles of RhoA/ROCK
signaling axis have been extensively explored in cancer and cancer related cells,
such as cancer associated endothelial cells [160, 188-193].
Under the circumstance of malignancy, decreased cell proliferation,
migration, and invasion, as well as increased apoptosis, were observed in different
types of cell lines when RhoA/ROCK signaling pathways were inhibited [194-200].
Meanwhile, different mechanisms such as reduced stress fiber and focal adhesion
formation, decreased expression of proteolytic enzymes, and cytoskeleton
rearrangement disorder [194, 195, 201] have been proposed to explain those
observed results. These findings highlighted the importance of RhoA/ROCK
signaling pathway in the cell motility, survival, proliferation, as well as gene
expression.
Moreover, RhoA/ROCK signaling pathway is also reported to play important
roles in the process of blood vessel formation [202, 203]. Expressed in endothelial
cells, RhoA/ROCK system is involved in the VEGF mediated angiogenesis, and
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inhibiting this signaling results in impaired precapillary cords formation and
endothelial migration [204-208]. In addition, human umbilical vein endothelial cells
(HUVECs) overexpressing RhoA display increased migratory and angiogenic
potency, which indicates the importance of RhoA signaling in endothelial cell
activities [209]. Previous findings indicated that RhoA affects the endothelial cell
functions mainly through regulating actin cytoskeleton organization [210]. In
addition, RhoA/ROCK pathway has been suggested to be an upstream regulator
of MAPK signaling molecules including ERK1/2, p38 MAPK, and JNK [211-213].
The MAPK pathways are closely associated with a variety of cellular activities [212,
214]. To be specific, the ERK1/2 pathway, which has been well studied, is involved
in cell growth, proliferation, differentiation, and migration [215]. Inhibition of ROCK
decreased the activation of ERK1/2 and consequently attenuated the cell migration
and proliferation in glioblastoma cells [214]. Recently, Zoledronate, which is used
to treat hypercalcemia in clinic, has been shown to attenuate the angiogenesis in
EPCs through inhibiting the activation of RhoA and MAPK signaling [216]. These
findings suggest the association of MAPK signaling and RhoA/ROCK pathway in
EPCs.
On the other hand, it has been demonstrated that interfering of CXCR2
mediated signaling transduction, either through CXCR2 neutralizing or CXCR2
knockout, has significant effect in endothelial cell migration and angiogenesis [217,
218]. Moreover, recruitment of EPCs from bone marrow to the sites of
neovascularization was also reported to be mediated by CXCR2 in mice [219]. In
addition, substantial evidence has accumulated that CXCR2 signaling activates
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the MAPK signaling molecules, including ERK1/2, p38 MAPK, and JNK, in a
variety of cell lines to regulate multiple cellular activities [220-223]. Interestingly,
RhoA also plays important roles in all these blood vessel formation related cellular
activities, such as migration, angiogenesis, and neovascularization. Taken
together, it is possible that CXCR2 mediated angiogenesis and neovascularization
are mediated through RhoA in endothelial cells and EPCs.
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CHAPTER 2 MATERIAL AND METHODS
2.1.

Antibodies and reagents
Anti-human and mouse CXCR2 and PLC-β3 antibodies as well as mouse

anti-NHERF1

monoclonal

antibody

were

purchased

from

Santa

Cruz

Biotechnology (Santa Cruz, CA). Rabbit anti-NHERF1 polyclonal antibody was
bought from Sigma-Aldrich. Recombinant chemokines, IL-8/CXCL8, growthregulated protein alpha (CXCL1/GROα/KC), and macrophage inflammatory
protein 2 (MIP-2/murine CXCL2) as well as growth factor VEGF (both mouse and
human) were obtained from ProSpec (East Brunswick, NJ). Growth factor reduced
Matrigel matrix, glutathione agarose beads and Transwell inserts were purchased
from BD Bioscience. The human and murine CXCR2 C-terminus peptides (biotinconjugate at N-terminus): WT (biotin-FVGSSSGHTSTTL for human CXCR2 C-tail;
and Biotin-FVSSSSANTSTTL for mouse CXCR2 C-tail) and PDZ motif deletion
(∆TTL) were synthesized by Genemed Synthesis, Inc. (San Antonio, TX). CXCR2
inhibitor

SB225002

was

purchased

from

Tocris

Bioscience.

Chariot TM

peptide/protein delivery reagent was purchased from Active Motif (Carlsbad, CA).
Lipofectamine 2000, Hanks’ buffered salt solution (HBSS), Fura-2 were obtained
from Invitrogen (Carlsbad, CA). GST PDZ fusion proteins (GST-NHERF1,
NHERF2, or PDZK1) were purified using glutathione agarose beads (BD
Bioscience), eluted with 50 mM glutathione, and used in pull-down. Fibronectin for
EPCs attachment in culture plate was purchased from BD biosciences (Franklin,
NJ).
2.2.

Plasmid, cloning, and mutagenesis
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C-terminal fragments of murine CXCR2 (last 45 amino acids; a.a. 315–359
for murine CXCR2) were generated by PCR cloning into pEGFP-C3 vector
(Invitrogen). CXCR2 C-terminus PDZ motif deletion mutation (ΔTTL) was
generated using the QuikChangeTM Site-directed Mutagenesis kit (Agilent
Technologies), and also cloned into pEGFP-C3 vector for plasmid construction.
2.3.

EPC isolation and culture
Mouse bone marrow (BM) cells were obtained by flushing the tibias and

femurs from wildtype C57BL/6J mice with PBS. The collected BM mononuclear
cells (MNCs) were isolated from collected bone marrow cells by density
centrifugation over Histopaque1083 (Sigma). The MNCs were then collected and
counted. Eighty million MNCs were seeded into each fibronectin (10 μg/ml) coated
60-mm petri dish with endothelial cell basal medium-2 (EBM-2) (Lonza)
supplemented with endothelial cell growth medium-2 (EGM-2) MV SingleQuots
(Lonza) containing FBS (5%), vascular endothelial growth factor (VEGF), fibroblast
growth

factor-B,

epidermal

growth

factor,

insulin-like

growth

factor 1,

hydrocortisone, ascorbic acid and antibiotics. Cells were cultured at 37°C with 5%
CO2. After 72 hours in culture, non-adherent cells were removed, and culture
medium was changed every other day. EPCs were characterized by incorporation
of DiI labeled acetylated low density lipoprotein (DiI-Ac-LDL) and staining of BSLectin I (Vector laboratories, Burlingame, CA), and flow cytometric analysis of
specific EPC surface markers (CD34 and VEGFR2) on day 7. During cultivation,
the morphological changes of EPCs were recorded using inverted microscopy.
Mouse BM-derived EPCs were also obtained from Celprogen Inc. (Torrance, CA).

33

The EPCs have been characterized by the Celprogen Company and are stained
positive for CD34, CD45, Sca-1, AP, and demonstrate incorporation of acetylated
LDL. The cells were maintained in EBM-2 supplemented with EGM-2 MV
SingleQuots, and sub-cultured every 2 days on murine fibronectin-coated culture
plates. The cells between passages 2–8 were used for the experiments.
Cell freezing and thawing were used to maintain the early passage batches
of cells for long term storage. Exponentially growing cells (approximately 80%
confluency) were treated with trypsin in a 37°C incubator. Then, 3 ml growth
medium were added to abrogate trypsin activity. The mixture was then transferred
to a 15-ml sterile tube and centrifuged at 100g for 7 min to harvest cell pellet. The
cell pellet was re-suspended in 5 ml freezing medium [growth medium containing
20% FBS and 10% (v/v) dimethyl sulfoxide (DMSO)]. Then aliquots of 1ml
containing 2 x 106 cells were transferred in cryogenic foam boxes at -80°C freezer
overnight and then immersed in liquid nitrogen. Cells were recovered from liquid
nitrogen by rapid thawing in a 37°C water bath, and then immediately resuspended in the appropriate pre-warmed culture medium and transferred to a 100
mm2 Petri dish, and medium was changed after 24 hours.
Human cord blood (CB)-derived EPCs (AC133 + progenitor cells) were
isolated from the cord blood obtained from volunteers under an Institutional Review
Board-approved protocol by the Henry Ford Health System. The cord blood MNC
population was generated by Ficoll gradient centrifugation and was enriched for
AC133 + cells by immune-magnetic positive selection using the MidiMACS system
(Miltenyi Biotec, Auburn CA) according to the manufacturer's protocol. Upon
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isolation AC133 + cells were suspended in CellGro® Stem Cell Growth Medium
(SCGM) (CellGenix) supplemented with 40 ng/ml of stem cell factor, 40 ng/ml of
FMS-like tyrosine kinase 3 and 10 ng/ml of thrombopoietin (all from CellGenix), as
described before [224]. Cells were maintained under these conditions at 37°C with
5% CO2 as a suspension culture to expand for up to 30 days with the cell
concentration kept between 5 × 105–1 × 106 cells/ml. For cellular functional
studies (such as adhesion and migration), primary AC133+ CB-EPC cells were first
differentiated in EGM-2 medium supplemented with 2% FBS and 2 ng/ml of VEGF
and plated in 6-well plate coated with human fibronectin at a concentration of
2 × 105 cells/ml. Cells were allowed to differentiate for 2 weeks. The medium was
changed every 2–3 days, and the cells were monitored by inverted phase contrast
microscopy to evaluate the morphological changes during differentiation, as
described before [224].
2.4.

Cell adhesion assay
ChariotTM peptide delivery reagent was used to deliver CXCR2 C-terminal

peptides (WT and ΔTTL) into the cells as reported before for adhesion assay.
Briefly, EPCs were cultured in fibronectin coated dishes until they reached 50%
confluency. CXCR2 C-tail peptides (WT and ΔTTL) diluted in sterilized water were
then mixed with ChariotTM reagent diluted in PBS at room temperature for 30 min
to form chariot-peptide complex. The complex was then incubated with EPCs at
37°C for 1 hour, and in the control group, EPCs were incubated with Chariot TM
reagent only under the same condition. The cells were then detached from culture
dish with trypsin. Ten thousand EPCs were seeded into each well of fibronectin
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coated 96-well plate at 37°C for 1 hour in starve medium (EBM-2 medium
containing 0.5% FBS) supplemented with 100ng/ml MIP-2. After 1 hour, nonadherent EPCs were removed by PBS washing and attached cells were quantified
by counting under 3 randomly selected high power field (HPF) in each well using
an inverted microscopy. Experiment was repeated three times and each condition
was triplicated.
2.5.

Chemotaxic migration assay
Chemotaxic migration assay was performed using 24-well cell culture insert

(BD bioscience) with 6.5-mm diameter polycarbonate filters (8-μm pore size) with
EPCs. Filter membranes were pre-coated with 0.1% gelatin diluted in migration
medium (0.5% FBS in EBM-2) for 2 h at 37 °C and air-dried afterward. EPCs in
culture dish were delivered with CXCR2 C-terminal peptides (WT or ΔTTL) or
ChariotTM reagent only, which was used as negative control, as described above.
EPCs were then detached and seeded in to each culture insert. EPCs (1 x 105) in
100μl of migration medium (0.5% FBS in EBM-2) were loaded in the upper
chamber of gelatin-coated Transwell, and 500μl migration medium containing MIP2 (100 ng/ml) was added in the lower chamber. The Transwell was then returned
to the 37 °C incubator for 3 h to allow the EPCs to migrate toward chemoattractant
gradient. After incubation, the remaining cells in the upper chamber were removed
by cotton swap. The migrated cells were fixed and stained with Diff-Quick stain kit
(IMEB, San Marcos, CA) according to the manufacturer’s protocol. Experiment
was repeated three times and each group was triplicated. Stained adherent cells
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were counted in 3 randomly selected fields per well using HPF under an inverted
microscopy.
2.6.

In vitro incorporation assay
EPCs were delivered with CXCR2 C-terminal peptides (WT or ΔTTL) or

ChariotTM reagent alone, which was used as negative control, as described above.
After that, EPCs were incubated with DiI-Ac-LDL (red fluorescence; Vector
Laboratories) in growth medium or, alternatively, incubated with Calcein Am (green
fluorescence, Invitrogen) in serum free medium according to the manufacturer’s
protocol respectively. Fluorophore-labeled EPCs (2 x 103), delivered with different
CXCR2 C-terminal peptides or delivery reagent, were co-cultured with human
dermal microvascular endothelial cells (HDMECs; 1 x 104) in growth factor reduced
matrigel (BD biosciences) coated 96-well plates (round bottomed) in EBM-2
medium containing 100ng/ml MIP-2. The cell mixture were kept in the 37°C
incubator for 3 hours to form tubular structure. The incorporated and nonincorporated EPCs were quantified using ImageJ software. The percentage of
incorporated EPCs was calculated and plotted. The proportion of EPCs in tubule
structures was determined in 10 random fields under a fluorescence microscopy.
2.7.

Generating stable transfected EPC cell line
EPCs were allowed to grow in culture plates till they reached 90%

confluency which is optimum for transfection. Then the cells were transfected with
pEGFP-C3 vector expressing different murine CXCR2 C-termini, WT and PDZ
motif deleted, (pEGFP-CXCR2 C-tail WT and pEGFP-CXCR2 C-tail ΔTTL) or
pEGFP-C3 vector alone into EPCs using lipofectamine 2000 reagent (Invitrogen)
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according to the manufacturer’s instruction. Cells were allowed to grow for another
48 hours and then were further diluted (1:1,000 dilution) and transferred into new
culture dish. Another plate with same amount of un-transfected cells was incubated
under the same condition as negative control. Stable expression of the constructs
in murine EPCs were obtained by using G418 sulfate selection. The expression of
GFP was confirmed by fluorescent microscopy and western blotting.
2.8.

In vivo matrigel plug angiogenesis assay
EPCs stably transfected with pEGFP-CXCR2 C-tail WT and pEGFP-

CXCR2 C-tail ΔTTL or the vector only were used in matrigel plug angiogenesis
assay. Briefly, 5 × 105 EPCs stably expressing CXCR2 C-tail constructs or vector
alone in 100μl of PBS were mixed with 500μl of growth factor reduced Matrigel
containing 40 units/ml heparin and 200ng/ml MIP-2. The Matrigel containing EPC
mixtures were implanted by a single subcutaneous injection into the mid-dorsal
region of wild-type C57BL6/J mice. Ten days after the injection matrigel plugs
containing EPCs expressing different constructs were collected. The obtained
matrigel plugs were prepared for histological study (H&E staining and anti-CD31
immunostaining). Microvessel density (CD31+ cells) was quantified and compared
in multiple mice between different groups where EPCs expressed different
constructs. Image analyses of the areas of CD31 + blood vessels, vessel number,
and length of vessel perimeter were carried out as reported [225]. All the animal
studies were accomplished under the protocol approved by Wayne State
University Institutional Animal Care and Use Committee.
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2.9.

Intracellular calcium mobilization assay
EPCs (2 × 106/ml) were delivered with CXCR2 C-terminal peptides (WT or

ΔTTL) or ChariotTM reagent alone as described above. The peptide-delivered
EPCs were then labeled with 5μM Fura-2 AM in HBSS buffer (Ca2+ and Mg2+ free)
at 37 °C for 45 min. The cells were then re-suspended in regular HBSS buffer at
the concentration of 106 EPCs/ml. Two milliliter re-suspended EPCs were loaded
into a continuously stirred cuvette at 37°C in a PTI fluorescence spectrophotometer
(Photon Technology International). The fluorescence of cell suspensions was
continuously monitored in a PTI fluorescence spectrophotometer at excitation
wavelengths of 340 nm and 380 nm, and emission wavelength of 510 nm. The
intracellular calcium concentration ([Ca2+]i) was expressed as the fluorescence
ratio at 340nm and 380nm (R). EPCs were stimulated with 100ng/ml MIP-2 once
the baseline was stabilized. At the end of each test, ionomycin (5μM, a calciumspecific ionophore) were added to trigger maximal fluorescence ratio (Rmax). After
that, 10mM EGTA (pH > 8) were added to chelate the Ca 2+ to obtain minimum
fluorescence ratio (Rmin). The intracellular calcium level (in nM) was proportional
to the ratio of fluorescence at 340/380. The equation describing this relationship is
as follows:
[Ca2+]i (nM) = Kd x [(R – Rmin) / Rmax – R] x Sfb
In this equation, Kd = 225 nM (under the condition that Ca2+ binds to Fura-2 AM
at 37°C), Sfb = ratio of fluorescence at 380nm under ionomycin and EGTA treated
conditions.
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2.10. Pull down assay
EPCs endogenously express CXCR2 were lysed in binding buffer (PBS +
0.2% Triton X-100) supplemented with a mixture of protease inhibitors (containing
1 mM phenylmethylsulfonyl fluoride, 1 μg/ml aprotinin, 1 μg/ml leupeptin, and
1 μg/ml pepstatin) and phosphatase inhibitor mixture (Sigma). Cell lysates were
mixed with the lysis buffer at 4°C for 15 min followed by centrifugation at 17, 000g
for 15 min at 4°C. The concentration of total proteins was measured with Bradford
method. Then the cleared supernatant was equally mixed with GST or different
GST fused PDZ domain containing proteins (GST-NHERF1, GST-NHERF2, and
GST-PDZK1) at 4°C for 2 h for direct binding. After 2 hours incubation, same
amount (20ul) of glutathione agarose beads (BD biosciences, San Jose, CA) were
equally added and mixed overnight at 4°C. Thereafter, the protein bound
glutathione agarose beads were pelleted by low speed centrifugation (800 x g,
1min) followed by three times of wash using lysis buffer to get rid of loosely bound
proteins. After that, the mixture of glutathione agarose beads and proteins were
eluted in Laemmli sample buffer containing β-mercaptoethanol. Eluted proteins
were subjected to western blotting to detect CXCR2.
2.11. Co-immunoprecipitation
EPCs were solubilized in binding buffer (PBS containing 0.2% Triton X-100)
supplemented with protease inhibitors (1 mM phenylmethylsulfonyl fluoride,
1 μg/ml aprotinin, 1 μg/ml leupeptin, and 1 μg/ml pepstatin). After centrifugation
(17,000 x g, 15 min at 4°C), cleared supernatant were collected and total protein
concentration was measured. Then the cleared lysates were processed for co-
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immunoprecipitation using a kit for co-immunoprecipitation (Thermo Scientific).
Resin from the kit was used to immobilize the normal IgG control and anti-CXCR2
IgG according to the manufacturer’s instruction. Co-precipitated proteins were
eluted in Laemmli sample buffer containing β-mercaptoethanol. Eluted proteins
were separated by SDS-PAGE and probed for PLC-β3 and NHERF1.
2.12. Western blot
Denatured proteins, either from total cell lysate or from binding assay elution,
were loaded onto Mini-PROTEAN TGX Gels (Bio-Rad) for separation. Then the
separated proteins were transferred to polyvinylidence fluoride (PVDF) membrane
(Bio-Rad) using Bio-Rad electrophoresis system. The transfer blot filter paper (BioRad) and the PVDF membrane (Bio-Rad) were pre-soaked in transfer buffer.
Transfer was carried out at a constant intensity of 60V for 90 min. Following
transfer, the membrane was then blocked in 5% non-fat dry milk solution in 1X
TBST (Tris-Buffered Saline and Tween 20) at room temperature for 1 hour and
incubated in primary antibody 1: 1,000 diluted with 1X TBST. Incubation was
carried out with gentle shaking at 4ºC overnight. The membrane was then washed
six times by gentle shaking in 1X TBST at room temperature. It was then incubated
with a suitable secondary antibody conjugated with the horseradish peroxidase
(HRP) 1:20,000 diluted in TBST-5% milk for 1 hour at room temperature with gentle
shaking. The membrane was then washed in TBST. The membrane was then
incubated with a mixture of the SuperSignal West Pico Chemiluminescent
Substrate (Pierce) or SuperSignal West Femto maximum sensitivity substrate
(Pierce) for 5 min at room temperature. The membrane was then exposed in UVP
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Biospectrum

500

imaging

system (UVP). The signals were obtained for 5 seconds to 30 minutes depending
on the intensity of the signals and the substrate that was used. The pictures were
processed using NIH ImageJ software.
2.13. EPC isolation and culture
Mouse BM-derived EPCs were obtained from Celprogen Inc. (Torrance,
CA). The EPCs have been characterized by the Celprogen Company and are
stained positive for CD34, CD45, Sca-1, alkaline phosphatase (AP), and
demonstrate incorporation of Dil-Ac-LDL. The cells were maintained in EBM-2
supplemented with EGM-2 MV SingleQuots, and sub-cultured every 2 days on
murine fibronectin-coated culture plates. The cells between passages 2–8 were
used for the experiments.
Cell freezing and thawing were used to maintain the early passage batches
of cells for long term storage. Exponentially growing cells (approximately 80%
confluency) were treated with trypsin in a 37°C incubator. Then, 3 ml growth
medium were added to abrogate trypsin activity. The mixture was then transferred
to a 15ml sterile tube and centrifuged at 100g for 7 min to harvest cell pellet. The
cell pellet was re-suspended in 5 ml freezing medium [growth medium containing
20% FBS and 10% (v/v) dimethyl sulfoxide (DMSO)]. Then aliquots of 1ml
containing 2 x 106 cells were transferred in cryogenic foam boxes at -80°C freezer
overnight and then immersed in liquid nitrogen. Cells were recovered from liquid
nitrogen by rapid thawing in a 37°C water bath, and then immediately re-
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suspended in the appropriate pre-warmed culture medium and transferred to a 100
mm2 Petri dish, and medium was changed after 24 hours.
2.14. Immunofluorescence staining
EPCs were seeded on glass coverslips pre-coated with fibronectin (10μg/ml)
until they reached 40% confluency and were starved in serum free medium before
stimulation. EPCs were then delivered with WT CXCR2 C-terminus peptide or
ChariotTM reagent alone before MIP-2 stimulation. At the same time, another group
of EPCs were pre-incubated with ROCK inhibitor (Y27632) for 1 hour as negative
control. After that the cells were then treated with 100ng/ml MIP-2 in serum free
medium for different time spans (0, 6, 12min) followed by washing with 37°C PBS
to remove stimulants. The cells were then fixed by 4% paraformaldehyde in PBS
(pH = 7.0) at room temperature for 10 min and washed with PBS at room
temperature for 30 min. The paraformaldehyde fixed cells were permeabilized in
PBS containing 0.5% Triton X-100 for 5 mins at room temperature followed by
washing with PBS for 30 min at room temperature to get rid of remaining detergent.
The coverslips were then transferred to a humid chamber and were incubated with
100nM Acti-stainTM 555 phalloidin (cytoskeleton Inc.) prepared in PBS at room
temperature in the dark for 30min to stain F-actin. Thereafter, the nuclei were
stained with 1μg/ml DAPI (Invitrogen) for 1 min. Then, the coverslips were washed
with PBS and inverted on a drop of mounting media on glass slides. Pictures were
taken under a fluorescence microscopy.
2.15. RhoA activation assay
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The activation status of RhoA was performed using RhoA pull-down
activation assay kit (Cytoskeleton, Inc.) according to the manufacturer’s instruction.
Briefly, EPCs were seeded into fibronectin coated plates till 40% confluency. Then
EPCs were starved in serum free medium followed by incubation with 100ng/ml
MIP-2 in serum free medium for 0, 1, 3, 6min. After chemokine stimulation, medium
was aspired and cells were washed with PBS followed by aspiration of PBS. Icecold lysis buffer provided by the kit was used to lyse the cells. After that, cell lysate
from each group were collected by cell scraper and clarified by centrifugation (10,
000 x g, 1 min at 4°C). After measurement of protein concentration, 25ug cell lysate
from each group was obtained and used as input and 400ug total cell lysate from
each group was used for pull-down assay. Same amount (50ug) rhotekin-RBD
beads, which specifically binds to activated RhoA, were used for pull-down in each
group. Binding was carried out at 4°C for 1 hour then the beads were pelleted.
When the binding was completed, the rhotekin-RBD beads were pelleted. The
proteins bound to the beads were eluted in Laemmli sample buffer containing βmercaptoethanol and boiled for 2 min. The eluted and denatured proteins were
then subjected to western blot to detect the bound activated RhoA as previous
mentioned except for the equilibration step. The equilibration was performed after
electrophoresis. During equilibration, the gel was immersed in western blot buffer
(containing 25mM Tris pH 8.3, 192mM glycine, and 15% methanol dissolved in
water).
2.16. MAPK and Akt signaling activation assay
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EPCs were cultured in fibronectin coated 6-well plates to reach 80%
confluency and were starved in serum free medium before stimulation. After
starvation, EPCs were delivered with WT CXCR2 C-terminus peptide or ChariotTM
reagent alone. Meanwhile, another group of EPCs were pre-incubated with 10μM
ROCK inhibitor Y27632 for 1 hour. Then cells from each group were stimulated
with 100ng/ml MIP-2 for different time spans (0, 1, 3, 6, and 12 min). Cells were
then washed with PBS to remove any remaining chemokines and were solubilized
in RIPA buffer (150 mM NaCl, pH 8.0, 50 mM Tris-base, 1% (v/v) Nonidet P-40,
0.5% (v/v) Na-deoxycholate, 0.1% (v/v) SDS) supplemented with protease inhibitor
cocktail (1 mM phenylmethylsulfonyl fluoride, 1 μg/ml of aprotinin, 1 μg/ml of
leupeptin, and 1 μg/ml of pepstatin) and a mixture of phosphatase inhibitors
(40mg/ml sodium fluoride, 20mg/ml sodium orthovanadate, and 65mg/ml sodium
pyrophosphate). Cells were lysed in 4°C for 15 min and were centrifuged to pellet
nuclei and cell debris. Cleared supernatant were collected and total protein
concentration was measured in each sample with Bradford method. After
concentration measurement, 20μg of each sample were mixed with Laemmli
sample buffer containing β-mercaptoethanol. Denatured proteins were subjected
to western blot to detect phosphorylation status of signaling molecules belonging
to MAPK pathway, such as Akt, JNK, p38MAPK, and ERK1/2.
2.17. Statistical analysis
All experiments are repeated at least three times. Analyzed data is
presented as mean ± SE. Statistical significance of differences was evaluated with
student’s t-test. When p < 0.05, the data was considered as statistically significant.
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CHAPTER 3 RESULTS
3.1.

CXCR2 PDZ-mediated macromolecular complex in EPC homing and
angiogenesis

3.1.1. Rationale
Angiogenesis, which is composed of endothelial cells migrate from preexisting blood vessels and proliferate to form blood vessels, was believed to be
the only mechanism of new blood vessel formation until Asahara and his
colleagues isolated EPCs twenty years ago [26, 226, 227]. Despite the debate of
EPC characterization and definition, our knowledge of EPCs biology has
extensively improved during the past two decades. Based on the morphological
and functional features, EPCs can be generally divided into two groups: early
EPCs and late EPCs. Early EPCs, which exist at the early stage in culture, possess
spindle shape and contribute to angiogenesis by producing angiogenic cytokines
such as IL-8 and VEGF. Late EPCs display cobblestone shape and express
different cell surface markers. Moreover, late EPCs with the potential of long term
proliferation, are able to incorporate into endothelial network and differentiate into
mature endothelial cells to facilitate new blood vessel formation [2, 20, 228-230].
Findings from preclinical studies have demonstrated the contribution of early and
late EPCs to the blood vessel formation under the condition of ischemia [25, 32].
It has been shown that these two groups of cells synergistically promote the
neovascularization, mainly through IL-8 secretion, when infused together into
animal model [32]. Due to the roles that EPCs play during angiogenesis and
neovascularization in a variety of disorders [12, 53, 231-234], they have been
considered to be a potential therapeutic target. However, administration of EPCs
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in clinical studies seems not fully encouraging [235]. Accordingly, deep
understanding of EPC biology, especially the underlying molecular mechanism of
the angiogenic and vasculogenic functions in EPCs, will significantly improve the
translational study.
It has been reported that both CXCR2 neutralizing antibody and CXCR2
depletion dramatically decreased endothelial cell migratory and angiogenic
capacities [217, 218]. Moreover, recruitment of EPCs from bone marrow to the
sites of neovascularization was also reported to be mediated by CXCR2 in mice
[219]. These studies have revealed the importance of CXCR2 in regulating cellular
functions during angiogenesis and neovascularization. Importantly, our recent
studies have further demonstrated that the PDZ motif located at the C-terminus of
CXCR2 is involved in regulating intracellular signaling transduction and cellular
functions in neutrophil and pancreatic cancer cells [50, 96]. In our studies, we
showed that NHERF1, a scaffolding protein containing two PDZ domains,
clustered CXCR2 and its downstream signaling molecule PLC-β to form
macromolecular complex through PDZ mediated protein-protein interactions in
neutrophil and pancreatic cancer cells. These multiprotein complexes were
involved in a variety of cellular activities, such as cell migration, proliferation, and
calcium mobilization. Therefore, it is possible that the CXCR2, through its PDZ
motif, can also interact with PDZ domain containing scaffolding proteins, which
further interact with other downstream proteins to form multiprotein complex in
EPCs. However, the existence of this PDZ mediated CXCR2 involved
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macromolecular complex as well as its influence in EPCs have not been evaluated
so far.
3.1.2. Results
3.1.2.1.

EPC isolation and characterization

In addition to using commercially available mouse EPCs (Celprogen Inc.),
EPCs were isolated from the tibias and femurs of C57BL/6J according to the
protocols previously reported [13, 29]. Isolated EPCs were cultured in EPC specific
medium for in vitro expansion. After 4 days of cultivation, the isolated EPCs
gradually adhered to the fibronectin coated growing surface and displayed spindleshaped morphology as shown in Figure 3.1.1A, which is similar to the morphology
reported by Asahara as well as others [2, 236]. Those attached cells were
characterized by DiI-Ac-LDL up-taking and FITC-conjugated BS-Lectin staining as
shown in Figure 3.1.1B. AC133+ EPCs isolated from human cord blood were also
cultured according to previously reported protocol [224] as shown in Figure 3.1.1C.
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Figure 3.1.1. EPC isolation and characterization.
(A). Morphology of EPCs isolated from mice bone marrow (BM-EPCs) in culture at
day 1, 7, and 14 (phase contrast images, 4x or 10x magnificent). (B). Images for
phase contrast, DiI-Ac-LDL (red) up-taking and FITC conjugated BS-Lectin I
(green), and nuclei staining (DAPI, blue) of bone marrow derived EPCs (10x
magnificent). (C). Morphology of EPCs isolated from human cord blood in cell
culture at day 1, 14, and 28 in cell culture (10 x magnificent).
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3.1.2.2.

CXCR2 signaling plays important roles in EPC migration and
angiogenesis in mice.

EPCs need to migrate toward and subsequently adhere to the angiogenic
active site to contribute to the formation of new blood vessels and CXCR2 is also
reported to be important in regulating angiogenesis. The role of CXCR2 was
evaluated in these processes in EPCs, including EPC migration, adhesion,
invasion, and incorporation into endothelial network. The commercially available
murine EPCs (Celprogen Inc.) were used in these experiments. The data shows
that compared with controls, EPCs, which were cultured in basal medium (EBM-2
containing 0.5% FBS), VEGF (used as positive control), MIP-2, and CXCL8
treatment significantly improved EPC migration (Figure 3.1.2), adhesion (Figure
3.1.3), invasion (Figure 3.1.4), and incorporation into endothelium tubular structure
(Figure 3.1.5) as shown in Figures respectively. On the other hand, MIP-2 and
CXCL8 mediated EPC migration, adhesion, incorporation into endothelium
network, and tubular structure formation were significantly attenuated by inhibiting
CXCR2 mediated signaling transduction through CXCR2 neutralizing antibody
[237] or CXCR2 antagonist SB225002 [238]. However, the promotive activities
generated by VEGF were not affected by CXCR2 signaling interfering, which is
consistent with previous findings [51, 219].

50

Figure 3.1.2 CXCR2 promotes murine EPCs migration.
Pictures (A) and Bar graphs (B) showed MIP-2, CXCL8, and VEGF (all 100ng/ml)
prmoted the migration of EPCs (pre-treated in goat serum); CXCR2 antiserum
(EPCs pre-treated with neutralizing antibody in goat serum) inhibited the MIP-2
and CXCL8 mediated EPCs migration but VEGF mediated EPC migration was not
affected (n=4, p < 0.05). (C) EPC migration was improved by MIP-2, CXCL8, and
VEGF (all 100ng/ml) and the promotive effect of MIP-2 and CXCL8 could be
inhibited by pre-incubation with CXCR2 antagonist SB225002. While VEGF
mediated increased migration was not affected by the CXCR2 antagonist preincubation (n=4, p < 0.05). (NT: no cytokine treatment, HPF: high power field).
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Figure 3.1.3. CXCR2 promotes murine EPC adhere to fibronectin.
Pictures (A) and bar graph (B) showed that MIP-2, CXCL8, and VEGF promoted
EPC adhere to fibronectin coated surface compared with EPCs without stimulation
(NT: no cytokine treatment). Pre-incubation of CXCR2 antiserum (goat serum
containing CXCR2 neutralizing antibody) significantly inhibited MIP-2 and CXCL8
promoted EPC adhesion but had not effect on VEGF promoted ECP adhesion to
fibronectin. (n=3, p< 0.05)
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Figure 3.1.4. CXCR2 promotes EPC invasion activity in vitro.
MIP-2, CXCL8, and VEGF (all 100ng/ml) facilitate the invasion of EPCs through
matrigel. The administration of CXCR2 antagonist SB225002 significantly
attenuated the promotive effect generated by MIP-2 and CXCL8 while had no
effect on VEGF promoted EPC invasion. (n=4, p < 0.05).
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Figure 3.1.5. CXCR2 promotes the incorporation of EPCs into endothelial network
in vitro.
DAPI labeled EPCs (blue), pre-incubated in goat serum, incorporation into
endothelium (HDMEC shown as transparent cells) tubular network in matrigel was
significantly improved by CXCR2 ligands, MIP-2 and CXCL8, and VEGF as shown
in fluorescent images (A) and bar graph (B). Pre-incubation of EPCs in CXCR2
antiserum significantly reduced the EPCs incorporation into endothelium tubule
structures in response to CXCR2 ligands, but had no apparent effect on VEGF
promoted increased incorporation. (n=4, p < 0.05).
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Human cord blood derived EPCs were also used to confirm the findings in
murine EPCs. Accordingly, the role of CXCR2 in human EPC migration and
incorporation into endothelial tubular structures were evaluated respectively.
Human cord blood EPCs were obtained as reported [224, 239-241]. The result
suggested that the migratory potential and the ability of incorporating into
endothelial tubular structure of EPC were increased in response to the CXCL8 and
VEGF compared to that of the cells without any treatment. Moreover, when EPCs
were pre-incubated with CXCR2 antagonist SB225002, the promotive effect of
CXCL8 on EPCs were significantly reduced, while promotive effect of VEGF on
EPCs were not apparently affected (Figure 3.1.6). These findings were consistent
with those from murine EPCs.
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Figure 3.1.6. CXCR2 promotes human EPC migratory and incorporative capacities
in vitro.
(A). Migration of human cord blood derived EPCs was promoted by CXCL8 and
VEGF (all 100ng/ml). The increased migration mediated by CXCL8 treatment was
significantly interfered by pre-incubation of EPCs with CXCR2 antagonist
SB225002 but that mediated by VEGF was not affected (n=4, p < 0.05). (B) EPCs
in vitro incorporation into HDMVEC tubule structure was facilitated by CXCL8 and
VEGF treatment (all 100ng/ml). The promoted incorporation mediated by CXCL8
was attenuated by pre-incubation with CXCR2 antagonist SB225002 but mediated
by VEGF was not affected significantly (n =3, p < 0.05) (NT: not cytokine treated,
SB: SB225002).
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3.1.2.3.

Disrupting CXCR2 PDZ motif-mediated interactions inhibits EPC in
vitro adhesion.

Our previous studies have demonstrated the importance of CXCR2 PDZ
motif (TTL) in facilitating CXCR2 mediated intracellular signaling transduction in
neutrophil and pancreatic cancer cells [50, 96]. It has been demonstrated that
CXCR2 is actively involved in EPC homing and angiogenesis [51, 219]. So it is
possible that the PDZ motif of CXCR2 is also involved in the CXCR2 mediated
EPC activities including migration, adhesion, invasion, and incorporation into
endothelial cell network. For this purpose, synthesized biotin labeled CXCR2 Cterminus containing PDZ motif (Biotin-FVSSSSANTSTTL; WT) or without PDZ
motif (Biotin-FVSSSSANTS; ΔTTL) were used for EPC functional assays in vitro.
Murine EPCs were firstly delivered with different CXCR2 C-terminal peptides (WT
or ΔTTL) or the delivery reagent alone (ChariotTM) and then were seeded onto
fibronectin coated culture dishes in starve medium (EBM-2 containing 0.5% FBS)
supplemented with or with MIP-2 (100ng/ml). After 1 hour, adherent cells were
counted. The result showed that the adhesion of WT CXCR2 C-terminus peptide
delivered EPCs to fibronectin in response to MIP-2 was significantly attenuated
compared to that of EPCs delivered with ChariotTM or ΔTTL CXCR2 C-terminus
peptide (Figure 3.1.7A). The same concept was also evaluated in human cord
blood derived EPCs. Human cord blood derived EPCs were delivered with human
CXCR2 C-terminus peptides with or without PDZ motif (WT or ΔTTL) or ChariotTM
alone. Then those cells were used for adhesion assay mediated by CXCL8. The
data showed that WT peptide delivery significantly inhibited the human cord blood
derived EPCs adhesion to fibronectin under the stimulation of CXCL8 (Figure
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3.1.7B). These findings indicated that PDZ motif of CXCR2 plays an important role
in EPC adhesion.
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Figure 3.1.7. WT CXCR2 C-terminus peptides delivery inhibited EPCs adhesion to
fibronectin mediated by CXCR2 signaling.
(A). Picture and bar graph of murine EPCs delivered with WT or ΔTTL CXCR2 Cterminus peptide, or ChariotTM reagent alone for adhesion assay under the
stimulation of MIP-2. WT peptide delivery significantly decreased the EPC
adhesion to fibronectin. (n = 4, p < 0.05) (B). Human cord blood derived EPCs
were also delivered with human WT or ΔTTL peptide or delivery reagent alone for
adhesion assay under the stimulation of CXCL8. WT peptide significantly
attenuated the EPC adhesion to fibronectin compared to those deliveries with
ΔTTL peptide or ChariotTM reagent alone. (n = 4, p < 0.05)
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3.1.2.4.

Disrupting CXCR2 PDZ motif-mediated interactions inhibits EPC in
vitro migration

Transwell migration assay were performed using both murine EPCs and
human cord blood derived EPCs. Similarly, EPCs were subject to delivery of
CXCR2 C-terminus peptides (WT or ΔTTL) or ChariotTM alone followed by
transwell migration assay. The results from transwell migration assay showed that
EPCs delivered with WT peptides displayed significantly reduced migratory
potential under the stimulation of MIP-2 or CXCL8, which was not observed in
EPCs delivered with ΔTTL peptides (Figure 3.1.8). These data indicated that
CXCR2 PDZ motif is important in EPC migratory activity in both human and mice.
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Figure 3.1.8. WT CXCR2 C-terminus peptides delivery inhibited EPCs migration.
(A). Picture and bar graph of murine EPCs delivered with WT or ΔTTL CXCR2 Cterminus peptide, or ChariotTM reagent alone for migration assay under the
stimulation of MIP-2. WT peptide delivery significantly decreased the MIP-2
induced EPC migration. (n = 4, p < 0.05) (B). Human cord blood derived EPCs
were also delivered with human WT or ΔTTL peptide or delivery reagent alone for
migration assay under the stimulation of CXCL8. WT peptide significantly
attenuated the EPC migration compared to that delivery with ΔTTL peptide or
ChariotTM reagent alone. (n = 4, p < 0.05)

61

3.1.2.5.

Disrupting CXCR2 PDZ motif-mediated interactions blocks EPC in
vitro incorporation into endothelial tubule structure.

It has been suggested that EPCs need to act in concert with pre-existing
endothelial cells to form blood vessels, but not to form new vessels de novo [64].
In addition, it has also been documented that CXCR2 neutralizing antibody
dramatically attenuated the incorporation of human EPCs into the arterial injury
site in the carotid arteries of athymic nude mice [51], indicating that CXCR2 play
an important role in the process of EPC incorporation. In order to evaluate the role
of CXCR2 PDZ motif-mediated interactions in the process of EPC incorporation
into endothelial tubular structure, CXCR2 peptides (WT or ΔTTL) or Chariot TM were
delivered into EPCs. After that, the cells were labeled with DiI-Ac-LDL and were
cultured with HDMECs in growth factor reduced matrigel respectively in the
presence of MIP-2. The result showed that WT peptide delivery significantly
interfered the incorporation of EPCs into endothelial tubular structure while ΔTTL
peptide delivery did not significantly affect the EPC incorporation induced by MIP2. (Figure 3.1.9)
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Figure 3.1.9. Disrupting PDZ-mediated interaction attenuated the incorporation of
EPCs to the endothelial tubular network
WT CXCR2 C-terminus peptides delivery significantly reduced the incorporation of
EPCs into the endothelial tubular network. While ΔTTL peptide delivery did not
achieve any significant inhibition on EPC incorporation compared to control group
which delivered with ChariotTM reagent alone. (n=3, p< 0.05)
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3.1.2.6.

Disrupting CXCR2 PDZ motif-mediated interactions decreases EPC
in vivo angiogenesis in mice.

EPCs have been reported to contribute to neovascularization through
incorporating into the vessel formation site and differentiating into mature
endothelial cells [242, 243]. In order to investigate the role that PDZ motif of
CXCR2 plays in EPC neovascularization in vivo, matrigel plug assay was
performed using murine EPCs. For this purpose, EPCs that stably express CXCR2
C-terminus peptide were established. Constructs expressing CXCR2 C-terminus
peptides that contains the last 45 amino acids of CXCR2 were cloned into pEGFPC3 vector (pEGFP-CXCR2 C-terminus WT). The PDZ motif deleted mutation
(pEGFP-CXCR2 C-terminus ΔTTL) was also generated with commercial available
mutagenesis kit. The generated constructs and empty vector (pEGFP-C3) were
then delivered into EPCs with lipofectamine 2000 separately. Stable cell lines
consistently expressing transfected constructs were obtained by G418 selection.
The expression of the constructs was evaluated by fluorescent microscopy and
western blot as shown in Figure 3.1.10.
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Figure 3.1.10. Stable cell lines expressing CXCR2 C-terminus peptides or GFP
only.
(A). Pictures of EPCs expressing pEGFP-C3 CXCR2 C-terminus WT or ΔTTL
under fluorescent microscopy. (B). Western blot detecting the expression of GFPCXCR2 C-terminus WT or ΔTTL peptides or GFP alone in EPC cell lysates (IB:
GFP).
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When the stable cell lines were established, the cells were used for matrigel
plug assay. EPCs expressing different CXCR2 C-terminus constructs were mixed
with growth factor reduced matrigel containing MIP-2. The matrigel containing
EPCs were subcutaneously injected into wildtype C57BL/6J mice. Ten days after
administration, the matrigel plugs were obtained and prepared for histological
investigations. Visually, less blood vessels were observed from the matrigel plug
containing EPCs expressing WT CXCR2 C-terminus compared to those containing
EPCs expressing vector alone or ΔTTL CXCR2 C-terminus. The matrigel plugs
were then subjected to H&E staining and immunohistochemistry (IHC) staining.
Data from H&E staining showed that the tubular structure formation was
significantly decreased in matrigel plugs containing pEGFP-C3 CXCR2 C-terminus
WT transfected EPCs compared with those containing EPCs expressing ΔTTL
CXCR2 C-terminus (Figure 3.1.11A). The expression of endothelial marker, CD31,
in the matrigel was also evaluated. The data from IHC demonstrated that the
expression of CD31 was significantly lower in WT group compared with ΔTTL
group (Figure 3.1.11B). The microvessel density represented by CD31+ cells were
quantified and compared among groups. The result showed that the microvessel
number in the matrigel from WT group was significantly lower than that from ΔTTL
and vector control groups (Figure 3.1.11C). The plugs from WT and ΔTTL groups
were homogenized and the homogenates were used for western blot to confirm
the expression of GFP fused CXCR2 C-terminus peptide (Figure 3.1.11D).
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Figure 3.1.11. Disrupting CXCR2 PDZ motif-mediated interactions reduces EPC
in vivo angiogenesis in mice
(A). H&E staining of newly formed blood vessels (arrows) in matrigels containing
EPCs transfected with pEGFP CXCR2 WT (left) or ΔTTL (right) C-termini. (B). IHC
staining of CD31 in matrigels containing EPCs expressing pEGFP CXCR2 WT (left)
or ΔTTL (right) C-termini. (C). Quantification of CD31 positive blood vessels in
matrigel plugs from matrigels with EPCs expressing pEGFP CXCR2 WT (left) or
ΔTTL (right) C-termini. (n= 5 mice in each group, p< 0.01) (D). Western blot using
anti GFP antibody to detect the expression of GFP fused CXCR2 WT (left) and
ΔTTL (right) C-terminus.
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3.1.2.7.

Disrupting CXCR2 PDZ motif-mediated interactions reduces
CXCR2-mediated EPC intracellular calcium mobilization

CXCR2 is able to couple to the pertussis toxin-sensitive Gi proteins to
stimulate phospholipase C (PLC) activities [50]. GPCR-induced PLC activation
catalyzes the hydrolysis of phosphatidylinositol 4, 5-bisphosphate (PIP2), resulting
in two second messengers: diacylglycerol (DAG) and inositol-1,4,5-trisphosphate
(IP3) which can trigger the intracellular calcium mobilization [244]. It is well
accepted that calcium signaling plays important roles in cytoskeletal reorganization
and cell migration [245, 246]. Recently, it has been reported that calcium signaling
is involved in the EPC migration toward the sites of neovascularization and
vascular remodeling [247]. In order to study the role of CXCR2 PDZ-mediated
interaction in calcium signaling in the cells, intracellular calcium mobilization assay
was performed in vitro. CXCR2 C-terminus peptides (WT or ΔTTL) or ChariotTM
reagent alone were delivered into murine EPCs separately. Then calcium
mobilization under the stimulation of MIP-2 (100ng/ml) was performed and the
results were calculated as described in the method. The result demonstrated that
the MIP-2 induced calcium mobilization was significantly attenuated in EPCs
delivered with WT CXCR2 C-terminus peptide, but not in those delivered with
ΔTTL CXCR2 C-terminus peptide or ChariotTM reagent alone (Figure 3.1.12).
These data suggested that PDZ-mediated interaction plays an important role in
calcium mobilization in EPCs.
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Figure 3.1.12. Disrupting CXCR2 PDZ-mediated interactions attenuated MIP-2
induced calcium mobilization in EPCs.
EPCs were delivered with different CXCR2 C-terminus peptide (WT or ΔTTL) or
ChariotTM respectively and were treated with MIP-2 (100ng/ml) to induce calcium
mobilization. The cells were incubated with Fura-2 (5μM) and the fluorescence was
monitored in a PTI fluorescence spectrophotometer under different wavelength.
The changes of intracellular calcium level (nM) in different groups were obtained
and calculated as previously described (Wu et al., 2012). (n=4, p < 0.01).
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3.1.2.8.

CXCR2 interacts with relevant signaling proteins via PDZ-based
interactions.

CXCR2 processes a consensus PDZ motif (-STTL-COOH) at its carboxyl
terminus, which could potentially bind to certain proteins containing PDZ motif.
Based on PDZ array (Panomics) and previous studies [50, 96] several PDZ
scaffold proteins which interact with CXCR2 through its C-terminal PDZ motif have
been identified. GST pull-down assay was performed to investigate whether
endogenous CXCR2 in EPCs interacts with PDZ scaffold proteins as previously
described [50]. EPCs were lysed and cleared cell lysate were incubated with GST
fused PDZ proteins (GST-NHERF1, GST-NHERF2, and GST-PDZK1) or GST for
binding. After that, the GST-fusion proteins with their bound proteins were pulldown by glutathione agarose beads for western blot to detect CXCR2. The result
demonstrated that CXCR2 was pulled down by NHERF1 rather than NHERF2 or
PDZK1 (Figure 3.1.13A), indicating that endogenous CXCR2 prefers to interact
NHERF1 in EPCs. In order to investigate if the binding between NHERF1 and
CXCR2 happens endogenously, co-immunoprecipitation assay was performed.
EPCs were lysed and cleared cell lysate were used for co-immunoprecipitation
according to the instruction of manufacturer. The result showed that endogenous
NHERF1 could be co-immunoprecipitated with CXCR2 in EPCs (Figure 3.1.13B).
As introduced above, CXCR2 couples to Gi, which is sensitive to pertussis
toxin, to active PLC-β isoforms. In addition, we have demonstrated that PLC-β2
forms multiprotein complex with CXCR2 and NHERF1 through PDZ-based
interaction in neutrophils [50]. We have also reported a NHERF1 interact with PLCβ43 and CXCR2 to form macromolecular complex in a PDZ dependent manner in
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pancreatic cancer cells [96]. More importantly, it was reported that PLC-β2
deficiency in EPC results in interfered migration and intracellular calcium
mobilization [247]. As demonstrated above, disrupting PDZ-mediated interactions
attenuated CXCR2 mediated calcium mobilization in EPCs, which suggests that
PLCβ isoform may form macromolecular complex with CXCR2 through PDZ based
interaction. For this purpose, co-immunoprecipitation assay was performed using
CXCR2 antibody. The data demonstrated that PLC-β3 was co-immunoprecipitated
with CXCR2 (Figure 3.1.13C). Like CXCR2, PLC-β3 also contains a PDZ motif at
its C-terminus [96], so it is highly possible that NHERF1, possessing two PDZ
domains, functions as a scaffold protein to cluster CXCR2 and PLC-β3 to proximity
to form a macromolecular complex through PDZ-mediated interactions to facilitate
specific and efficient signaling transduction in EPCs.
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Figure 3.1.13. CXCR2 interact with NHERF1 and PLC-β3 through PDZ-mediated
interactions.
(A). endogenous CXCR2 was pulled down by GST NHERF1 protein. (B).
Endogenous NHERF1 was co-immunoprecipitated with endogenous CXCR2 in
EPC. (C). Endogenous PLC-β3 was co-immunoprecipitated with endogenous
CXCR2 in EPC.
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3.1.3. Discussion
A large body of evidence has accumulated to indicate that EPCs, which is
considered to be a group of cells that are derived from bone marrow, have the
capacity to migrate, proliferate, and differentiate from progenitor phenotype into
mature endothelial cells in a variety of systems. EPCs have been demonstrated to
be important in adult neovascularization and contribute to vascular repair as well
as tumor growth [2, 248]. The homing of EPCs toward the new blood vessel
formation sites is a complex process which includes chemotactic migration,
invasion, adhesion, incorporation, and finally differentiation [243]. These
processes are regulated by a variety of biologically active factors such as cytokines,
chemokines, and growth factors. During two decades of investigation of EPC
biology, CXCR2 and CXCR4 and their ligands have been reported to play critical
roles in EPC homing through regulating EPC mobilization, recruitment, and firm
adhesion injury [51, 162, 219, 249-251]. Although EPCs have been studied for two
decades in different areas, the underlying mechanisms of how EPCs contribute to
postnatal neovascularization still needs further investigation.
CXCR2 possesses a PDZ motif at its C-terminus, and the PDZ motif has
been reported to modulate CXCR2 mediated cellular chemotaxis [252]. We have
recently demonstrated the role of PDZ mediated CXCR2 involved macromolecular
complex in neutrophil and pancreatic cancer cells. In neutrophils, disrupting PDZmediated interaction by exogenous peptide (short peptide containing CXCR2 PDZ
motif) significantly interrupted CXCR2-mediated calcium mobilization and
migration [50]. Similarly, in pancreatic cancer cells, introducing exogenous peptide
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containing CXCR2 PDZ motif has significantly attenuated proliferation and
invasion in vitro and inhibited tumor growth in vivo [96].
In this study, the importance of CXCR2 PDZ-mediated interaction in EPC
motility and angiogenic potency has been demonstrated through functional assays
and biochemical studies. Through introducing exogenous CXCR2 C-terminus
peptide (WT or PDZ motif deleted) or stably transfecting DNA constructs
expressing CXCR2 C-terminal fragments into EPCs, the CXCR2 PDZ-mediated
interactions have been interrupted. Consequently, the abilities of EPCs
incorporating

into

endothelium

network

(Figure

3.1.9)

and

postnatal

neovascularization (Figure 3.1.11) was significantly interfered. Moreover, the
intracellular calcium mobilization was also affected due to the interrupted CXCR2
PDZ-mediated interaction (Figure 3.1.12). Based on our previous findings, these
results indicated that a PDZ-mediated CXCR2 involved multiprotein complex may
be formed in EPCs to regulate those cellular activities. A growing body of evidence
indicate that proteins containing PDZ domains function as scaffolding proteins to
cluster multiple proteins to form macromolecular complexes which promote
specific and efficient signaling transduction [145, 253-255].
It has been reported that antiserum against the PDZ motif of shCD146,
which is a cell adhesion molecule, inhibited the adhesion of EPCs to activated
endothelial cells. This study indicated that PDZ motif plays important roles in EPC
biology [256]. Recently, we have also demonstrated that NHERF1 clustered
CXCR2 and PLC-β to proximity in neutrophil and pancreatic cancer cells to
regulate CXCR2 mediated signaling transduction [50, 96]. We further reported the
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crystal structures that demonstrated the interaction between NHERF1 and CXCR2
as well as NHERF1 and PLC-β3 [146, 147, 257]. PLC-β isoforms have been
documented to be involved in GPCR-mediated cellular activities. Among the 4
members of PLC-β family, PLC-β3 is widely expressed in different tissues [258]
and can be activated by Gβγ subunits [259]. PLC-β3 has been reported to interact
with PDZ domain containing proteins including NHERF1 and NHERF2 through the
PDZ motif located at its C-terminus in a variety of cell lines [260-262]. Based on
these findings, it is reasonable to speculate that the PDZ-mediated CXCR2
involved multiprotein complex may also exist in EPCs to regulate signaling
transduction. In the present study, the biochemical assay demonstrated that in
EPCs NHERF1 clustered CXCR2 and PLC-β3 to form macromolecular complex.
Accumulating evidence suggested that the assembly of the macromolecular
complex beneath cellular membrane facilitated the transduction of signals from
environment into the cells, which subsequently affected the cellular activities
specifically and efficiently [50, 263-266]. Furthermore, functional assays
suggested the importance of this multiprotein complex in EPC recruitment and
incorporation into endothelial tubule structure.
These findings suggested a therapeutic implication of PDZ-mediated
CXCR2 involved multiprotein complex in diseases related to blood vessel
formation. EPCs are involved in a variety of disorders including pathologic
angiogenesis, tumor progression, and airway remodeling in asthma [219, 249, 267,
268]. Therefore, inhibiting the angiogenic potency of EPCs may provide an
approach to control new blood vessel formation in these disorders. In vivo matrigel
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plug assay has demonstrated that competing the PDZ-mediated interaction
between CXCR2 and NHERF1 by introducing CXCR2 C-terminus peptides into
EPCs has significantly hindered the EPC involved blood vessel formation. These
findings have supported the notion that targeting PDZ-mediated interaction in EPC
may have therapeutic implication in angiogenesis related diseases. In addition,
Aarts et al. reported that disrupting the PDZ based interaction between N-methylD-aspartate receptor (NMDAR) and PSD-95 has inhibited the activation of
neuronal nitric oxide synthase (nNOS), which subsequently reduced the stroke
induced brain injury [269]. Moreover, the PDZ domain of adaptor protein PICK1
has recently been identified as a potential therapeutic target for neuropathic pain,
excitotoxicity, and cocaine addiction [270, 271]. Therefore, targeting PDZmediated CXCR2 involved macromolecular complex in EPC may convey
promising therapeutic implication in diseases associated with blood vessel
formation such as tumor progression.
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3.2.

RhoA is involved in CXCR2 signaling in EPC

3.2.1. Rationale
Substantial proof has accumulated that CXCR2 signaling activates the
MAPK signaling molecules, including ERK1/2, p38 MAPK, and JNK, in a variety of
cell lines to regulate multiple cellular activities [220-223, 272]. It is well accepted
that MAPK signaling pathway regulates cell migration in cancer cells [273],
endothelial cell [274], and EPCs [216]. MAPK signaling is important in the process
of angiogenesis due to its contribution to the migratory and proliferation in
endothelial cells and EPCs, which are critical events in angiogenesis. On the other
hand, the regulatory effects of CXCR2 on the motility and angiogenic activities in
EPCs has been reported as well. Li et al. also reported that EPC mobilization and
neovascularization were significantly hindered in CXCR2 knockout mice [45].
Furthermore, the promotive role of CXCR2 in angiogenesis have been well
appreciated [217, 275]. These findings indicate the putative involvement of MAPK
signaling in the CXCR2 regulated EPC functions.
Another important signaling effector downstream of CXCR2 is PI3K/Akt. It
has been demonstrated that PI3K/Akt and MAPK are involved in CXCR2 mediated
actin remodeling in neutrophil [276]. Moreover, PI3K/Akt signaling is also involved
in CXCR2 mediated chemotaxis and the process of epithelial-mesenchymal
transition (EMT) [277, 278]. More importantly, PI3K/Akt has been reported to
contribute to EPCs involved angiogenesis [279]. It is reasonable to propose that
CXCR2 may regulate the homing and angiogenesis in EPCs through PI3K/Akt
and/or MAPK signaling pathways.
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Interestingly, accumulating evidence has shown that RhoA is associated
with the activities of both MAPK and PI3K/Akt signaling. It has been recently
reported that RhoA is involved in the regulation of MAPK signaling activation in
EPCs [216]. RhoA/ROCK pathway has been suggested be an upstream regulator
of MAPK signaling molecules including ERK1/2, p38 MAPK, and JNK [211, 212,
280]. Inhibition of ROCK decreased the activation of ERK1/2 and consequently
attenuated the cell migration and proliferation in glioblastoma cells [214]. Recently,
Zoledronate, which is used to treat hypercalcemia in clinic, has been shown to
attenuate the angiogenesis in EPCs through inhibiting the activation of RhoA and
MAPK pathway [216]. Meanwhile, RhoA also regulates the activity of PI3K/Akt
signaling in a variety of cell lines. For instance, activated by RhoA, PI3K/Akt/MAPK
signaling leads to upregulated production of hepatic growth factor in macrophage
[281]. In addition, C3 exoenzyme, an inhibitor of RhoA, inhibited the activation of
Akt in endothelial cells [282], indicating that RhoA activates Akt in endothelial cells.
These findings provide the possibility that RhoA/ROCK pathway may be also
involved in regulating MAPK and PI3K/Akt signaling in EPCs.
RhoA activity is regulated by a variety of upstream signaling molecules. It
has been reported that MIP-2, which is one of the murine CXCR2 ligands, activated
RhoA in murine endothelial cells. Moreover, inhibition of RhoA signaling through
ROCK inhibitor or siRNA targeting RhoA has significantly decreased endothelial
cell migration during MIP-2/CXCR2 mediated angiogenesis [283]. Furthermore,
CXCL8 has also been shown to be responsible for the actin cytoskeleton
rearrangement for assembly of stress fibers and membrane ruffling through Rac1
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and RhoA mediated signaling in HUVECs to promote the cell migration. In addition,
dominant negative RhoA and constitutively active RhoA mutations were able to
attenuated and facilitate CXCL8 mediated endothelial cell migration respectively,
indicating the regulatory capacity of RhoA in this process [284]. It has been
demonstrated that LIX, and MIP-2 and their cognate receptor CXCR2 are actively
involved in ischemia induced angiogenesis, and blockade of CXCR2 diminished
this process. Importantly, significant activation of RhoA has also been observed
during this CXCR2 mediated angiogenesis [285]. All these findings have
highlighted the importance of RhoA in CXCR2 signaling pathway.
Taken together, it is reasonable to hypothesize that CXCR2 regulates EPC
migration and angiogenesis in a RhoA/ROCK, PI3K/Akt, and MAPK dependent
manner.
3.2.2. Results
3.2.2.1.

MIP-2 treatment results in activation of RhoA in EPCs

It is known that cell motility requires cells to experience alternating phases
of protrusion and contraction. During migration, cells attach and adhere to the
substrate such as ECM, and the adhesion provides the force for the cell body
contraction and tail retraction. RhoA regulated stress fiber plays critical roles in
these processes [286, 287], such as promoting cell adhesion and migration [288].
In my data, I have demonstrated that MIP-2 induced the migration of EPCs (Figure
3.1.8). Moreover, it has been reported that MIP-2 was able to activate RhoA in
endothelial cells to contribute to neovascularization [283, 285]. However, whether
RhoA is involved in MIP-2 mediated migration in EPCs has not been studied. I
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hypothesize that MIP-2 may activate RhoA through CXCR2 in EPCs to modulate
EPCs functions. RhoA activation assay was used to test this hypothesis. In this
assay, EPCs were incubated with MIP-2 for 0, 1, 3, and 6 min and were lysed.
Then, the same amount of cleared cell lysates (400μg) from each group was used
for GST-Rhotekin pulldown assay, and 5% of total cell lysate in each group was
used as input. The amount of active RhoA present in the cells was determined by
western blotting. Figure 3.2.1 demonstrated that RhoA was activated in EPCs by
MIP-2 (100ng/ml). The data showed that RhoA was activated 6 min after the MIP2 was administrated. This data demonstrated that RhoA could be activated by MIP2/CXCR2 signaling pathway in EPCs.

Figure 3.2.1. MIP-2 activated RhoA in EPCs.
Upper panel shows that RhoA was activated by MIP-2 (100ng/ml) after 6 min of
stimulation in EPCs. Lower panel shows the input (5% of cell lysate used for
pulldown assay), which was used as loading control.
3.2.2.2.

PDZ-mediated interaction is involved in the activation of RhoA

From the previous data, I have demonstrated that MIP-2/CXCR2 mediated
EPCs migration, which could be attenuated by interrupting CXCR2 PDZ motif
mediated interaction within the cells (Figure 3.1.8). Meanwhile, I have also shown
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that RhoA, which provides forces for cell body contraction and tail retraction during
cell migration [286, 287], was also activated by MIP-2 treatment (Figure 3.2.1).
While whether the CXCR2 PDZ motif-mediated interaction is involved in MIP-2
induced RhoA activation has not been investigated. RhoA and its major effector,
ROCK, regulate actin reorganization to promote the assembly of focal adhesions
and formation of actin stress fibers [289, 290]. I hypothesize that CXCR2 PDZ motif
mediated interaction may play a role during the MIP-2 induced activation of RhoA.
In order to test my hypothesis, I pre-incubated EPCs with ROCK inhibitor Y27632
for 1 hour or delivered CXCR2 C-terminus peptide or ChariotTM reagent alone into
EPCs before MIP-2 stimulation. Then cells were stimulated with MIP-2 (100ng/ml)
for 0, 6, 12 min respectively. After that, immunofluorescence staining was
performed to detect the actin formed stress fibers in each group. Figure 3.2.2
showed that stress fibers could be observed in the control group (left column), in
which EPCs were delivered with ChariotTM reagent alone, 6min after MIP-2
stimulation. No stress fiber was observed in the Y27632 pre-incubated group (right
column). However, compared to the control group, the formation of stress fibers in
EPCs was delayed (observed 12min after MIP-2 treatment) and attenuated when
the CXCR2 C-terminus peptide was delivered into EPCs as shown in the figure
(middle column), indicating that CXCR2 PDZ motif-mediated interaction in EPCs
is involved in activation of RhoA.
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Figure 3.2.2. Disrupting CXCR2 PDZ motif-mediated interaction attenuated the
activation of RhoA.
RhoA activation in EPCs was reflected by stress fiber formation after MIP-2
stimulation. Left column: Stress fibers were formed 6min after MIP-2 (100ng/ml)
treatment in EPCs delivered with ChariotTM reagent alone. Middle column: In EPCs
delivered with CXCR2 C-terminus PDZ peptide, the stress fibers were formed
12min after MIP-2 (100ng/ml) treatment in EPCs, which was delayed compared to
that in control group. In addition, the strength of the signal was weak compared to
that in control group. Right column: The MIP-2 induced formation of stress fibers
were barely observed in EPCs pre-incubated with ROCK inhibitor Y27632.
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3.2.2.3.

RhoA is involved in the MIP-2/CXCR2 signaling pathway

It has been reported that CXCR2 signaling activates the MAPK signaling
and PI3K/Akt signaling to regulate a variety of EPC functions including,
mobilization, migration, and proliferation [43, 280]. Meanwhile, RhoA/ROCK has
also been reported to regulate PI3K/Akt and MAPK signaling in endothelial cells
and EPCs [283, 215]. Moreover, a clinical used drug to treat hypercalcemia,
Zoledronate, has been reported to attenuate the angiogenic potential of EPCs by
inhibiting the activities of RhoA and MAPK signaling [215]. My data has shown that
MIP-2/CXCR2 signaling activated RhoA to form stress fiber, which is important in
EPC migration and angiogenesis, and this activation was attenuated by disrupting
CXCR2 PDZ motif mediated interaction in EPCs. It is possible that MAPK signaling
or PI3K/Akt signaling may be involved in the MIP-2 induced EPC migration and
disrupting PDZ mediated interactions would affect the activation of these signaling.
In order to test this hypothesis, EPCs were starved and pre-incubated with Y27632,
or delivered with WT CXCR2 C-terminus peptide or ChariotTM reagent alone before
MIP-2 stimulation. Then cells were treated with MIP-2 (100ng/ml) for 0, 1, 3, 6, and
12min respectively. After that the activation status of JNK, p38, ERK1/2, and Akt
has been detected and compared among different groups as shown in Figure 3.3.
The data shows that MIP-2 induced the phosphorylation of p38 (Figure 3.2.3.A),
ERK1/2 (Figure 3.2.3.B), and Akt (Figure 3.2.3. C and D) in EPCs, but not JNK
(data not shown), indicating that these molecules could be activated by CXCR2
signaling. In addition, introducing WT CXCR2 C-terminus peptide into the EPCs to
compete the PDZ mediated interactions attenuated the phosphorylation of those
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molecules, indicating that CXCR2 PDZ motif-mediate interactions plays important
role in CXCR2 mediated MAPK and PI3K/Akt activation. Moreover, Y27632 preincubation has also inhibited the activation of those CXCR2 activated signaling
molecules, which suggests that RhoA/ROCK is also involved in CXCR2 mediated
MAPK and PI3K/Akt signaling transduction.

Figure 3.2.3. RhoA/ROCK and PDZ-mediated interaction is involved in CXCR2
induced activation of p38, ERK1/2, and Akt.
EPCs were pre-incubated with Y27632, or delivered with WT CXCR2 C-terminus
peptide or ChariotTM reagent alone before followed by starvation and MIP-2
stimulation for 0, 1, 3, 6, and 12min. The data has shown that MIP-2 activated p38
(A, upper panel), ERK1/2 (B, upper panel), and Akt (C and D, upper panel) in EPCs
after 3 min incubation (upper panel), while the activation of p38 was not observed
in WT CXCR2 C-terminus peptide delivered EPCs (A-D, middle panel) and Y27632
pre-incubated EPCs (A-D, lower panel).
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3.2.3. Discussion
The importance of EPC in postnatal vascularization indicates its therapeutic
potential. EPCs are involved in a variety of blood formation related disorders. Their
instructive function (secret pro-angiogenic factors) and constructive function
(incorporation and differentiation) are dysfunctional in cardiovascular diseases and
diabetes which require blood vessel formation [9, 10, 72, 77, 78]. On the other
hand, in the malignancies, EPCs contribute to tumor growth and progression
through promoting angiogenesis [59-61]. So it is necessary to understand the
underlying mechanism that regulates EPCs functions in these disorders. This
study has shown that interrupting PDZ mediated interaction in EPCs attenuated
the cell adhesion (Figure 3.1.7), migration (Figure 3.1.8), and angiogenesis (Figure
3.1.11). These studies have suggested the potential therapeutic value of CXCR2
PDZ motif-mediated interaction within EPCs. However, the underlying mechanism
of how this PDZ-mediated interaction affect the cellular function has not been fully
studied. Results from this study showed that RhoA, which is responsible for the
formation of stress fibers and focal adhesions that play important roles in cell
migration, was activated through MIP-2/CXCR2 axis (Figure 3.2.1). I have further
demonstrated that interrupting PDZ mediated interaction in EPCs attenuated the
MIP-2 induced stress fiber formation (Figure 3.2.2). Moreover, disrupting PDZ
mediated interactions in EPCs have also attenuated the MIP-2 induced
phosphorylation of p38 MAPK, ERK1/2, and Akt. In addition, similar results were
observed when RhoA/ROCK signaling was inhibited in the cells (Figure 3.2.3).
These results suggested that RhoA/ROCK and MAPK as well as PI3K/Akt may
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contribute to the MIP-2 mediated chemotaxis of EPCs and PDZ mediated
interactions may play a role in regulating the signaling transduction. This study has
provided a potential signaling transduction pathway in regulating EPCs function.
However, the exact role of each signaling molecules remains mysterious, which
directs future studies toward the investigation of their functions during this process.
It is worthy to determine the signaling cascades or network that are involved in this
regulation process which could be helpful in identifying specific and efficient
therapeutic target.
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CHAPTER 4 CONCLUSION AND FUTURE DIRECTION
4.1.

Conclusion
Derived from bone marrow, EPCs contribute to the adult vascularization

through secreting pro-angiogenic factors and incorporating into angiogenic sites to
differentiate into mature endothelial cells [4, 18]. The functions of EPC reflect its
importance in physiological and pathological conditions. Mobilized by a variety of
factors, EPCs will home to the sites of ischemia or vascular injury to promote the
blood vessel formation [49-51]. Thus, a comprehensive understanding of the
biology of EPC and the underlying mechanisms that regulate its homing and
angiogenic activities could be helpful to identify potentially disease specific
molecular targets in the cells for developing improved therapies.
My research has demonstrated that the PDZ motif of CXCR2 plays
important roles in EPC motility and angiogenic activity in vivo and in vitro.
Disrupting the CXCR2 PDZ motif-mediated interactions in EPCs attenuated
neovascularization, incorporation into endothelial network, and migration.
Moreover, based on our previous finding of PDZ based CXCR2 involved
macromolecular complex in neutrophil and pancreatic cancer cells [50, 96], the
biochemical study of my research has suggested a CXCR2-NHERF1-PLCβ3
complex in EPCs. In addition, I have also studied the possible mechanism that
CXCR2 PDZ-mediated interaction affects EPC functions. I have found that the
chemotaxis stimulus of EPCs activated RhoA in the EPCs and disrupting the
CXCR2 PDZ-mediated protein-protein interactions attenuated the activation of
RhoA as well as downstream signaling molecules including p38 MAPK, ERK1/2,
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and Akt. The findings suggest the involvement of these signaling molecules in the
CXCR2 mediated EPC cellular activities and also indicates their activations can be
regulated by CXCR2 PDZ mediated interaction. My study, for the first time,
demonstrated the importance of CXCR2 PDZ motif-mediated interaction in EPC
biology and provided the potential involved signaling pathways. These findings
contribute to our understanding of EPC biology and may be valuable in
identification of novel therapeutic targets. My dissertation study provides the
possibility that targeting the CXCR2 PDZ motif-mediated macromolecular complex
is an effective approach to regulate the EPC dependent angiogenesis in different
diseases.
4.2.

Future direction

4.2.1. The role of MAPK signaling and PI3K/Akt signaling pathways in
cellular functions have been intensively investigated.
The MAPK signaling is composed of p38 MAPK pathway, MEK/ERK
pathway, and JNK pathway [220-222]. It is well documented that p38 MAPK,
ERK1/2, and Akt are involved in cell migration [216, 278] and angiogenesis [279,
291-293]. Although I have shown in my results that disrupting CXCR2 PDZ motifmediated interaction attenuated the activation of p38 MAPK, ERK1/2, and Akt
under the stimulation of MIP-2 in EPCs, it is still not known their exact role of them
during MIP-2 induced EPC cellular activities. In order to have a more
comprehensive understanding of the mechanisms that PDZ mediated interaction
regulates EPC homing and angiogenesis, inhibitory studies will be performed.
I speculate that the contribution of three signaling pathways in EPC
functions are not equal. To test my hypothesis, I will block p38 MAPK (using
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SB203580), ERK1/2 (U0126), or Akt (MK2206) signaling pathways in EPCs
separately and perform EPC migration assay, adhesion assay, and in vitro tube
formation assay under the stimulation of MIP-2. EPCs without inhibitor treatment
will be used as negative control. I will observe the effects of different inhibitors on
EPCs adhesion, migration, and in vitro angiogenesis to study how the three
signaling pathways are involved in each EPC function.
In parallel, I will also knockdown the expression of p38 MAPK, ERK1/2, or
Akt by transiently transfect commercial available siRNAs targeting each signaling
molecule respectively in EPCs. EPCs incubated with transfection reagent alone
will be used as negative control. After the silencing each of the signaling molecules,
I will stimulate the EPCs with MIP-2 and perform adhesion, migration, and in vitro
tube formation assays. The effect of each pathway inhibition on each EPC function
will be recorded and compared to study how the three signaling pathways are
involved in each EPC function.
4.2.2. Further study the PDZ mediated interaction on RhoA activation.
As a member of small GTPase, the activity of RhoA is regulated by
nucleotide exchange factors (GEF) and GTPase-activating proteins (GAP). My
dissertation results showed that RhoA activation was affected by CXCR2 PDZ
motif-mediated interactions (Figure 3.2.2). However, how did the PDZ-based
interaction influence RhoA activation is still unclear. Our previous findings in
neutrophil and pancreatic cancer cells [50, 96] have suggested the presence of
PDZ-mediated CXCR2 involved complex in the cells to promote efficient and
specific signaling transduction. Thus, I hypothesize that CXCR2 may form a protein

89

complex through its PDZ motif-mediated interaction with GEF to facilitate RhoA
activation and disrupting this PDZ-mediated interaction would attenuate the
activation of RhoA.
I will perform immunoprecipitation followed by liquid chromatographytandem mass spectrometry (LC-MS/MS) to detect CXCR2 bound proteins
mediated by PDZ-based interaction. To do this, I will clone full length CXCR2 or
CXCR2 without PDZ motif with 3HA tagged at N-terminus into pcDNA3.1 vector
(pcDNA3.1-3HA-CXCR2-FL; pcDNA3.1-3HA-CXCR2-dTTL). After that, I will
transfect EPCs with pcDNA3.1-3HA-CXCR2-FL, pcDNA3.1-3HA-CXCR2-dTTL, or
pcDNA3.1 vector alone respectively and stimulate cells with MIP-2. Then cells from
each group will be lysed and 3HA tagged CXCR2-FL or CXCR2-dTTL and their
bound proteins will be immunoprecipitated by anti HA agarose. The precipitated
proteins will then be eluted and separated in a SDS-PAGE gel and digested to
produce peptide for the tandem mass spectrometry to identify the bound proteins.
After that, identified proteins from EPC expressing CXCR2-FL, CXCR2-dTTL, and
pcDNA3.1 empty vector will be compared to obtain unique proteins including GEFs
only found in CXCR2-FL group. It is possible that the list of unique proteins may
contain the potential adaptor protein or GEFs containing PDZ domain.
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Bone marrow-derived endothelial progenitor cells (EPCs) participate in
postnatal vascularization in response to growth factors, cytokines, and
chemokines. Chemokine receptor CXCR2 and its cognate ligands are reported to
mediate EPC recruitment and angiogenesis. CXCR2 possesses a consensus
PSD-95/DlgA/ZO-1 (PDZ) motif at its carboxyl terminus. The PDZ motif has been
reported to regulate cellular signaling and functions. Here we investigated the
potential role of the PDZ motif in CXCR2-mediated EPC motility and angiogenesis.
We have found that introducing exogenous CXCR2 C-terminus significantly
attenuated in vitro EPC migration and angiogenic activities in response to CXCR2
ligands, as well as in vivo EPC angiogenesis. Meanwhile, the activation of RhoA,
p38, ERK1/2, and Akt has also been inhibited due to the exogenous CXCR2 Cterminus. On the other hand, delivering CXCR2 C-terminus without PDZ motif into
EPCs did not significantly affect the functions of EPCs. Moreover, biochemistry
study suggested that NHERF1, a PDZ domain containing scaffolding protein,
preferred to interact with CXCR2 and its downstream effector, PLC-β3 in EPCs.
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Taken together, the data has demonstrated the role of CXCR2 PDZ motif-mediated
macromolecular complex in EPC homing and angiogenesis and also indicated
potentially involved signaling pathways. The findings suggested that targeting
CXCR2 PDZ motif-mediated interactions in EPCs may be a novel therapeutic
approach in EPC dependent angiogenesis related diseases.
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